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FUNCTIONAL	REGULATION	OF	YAP	BY	AURORA	A	KINASE	IN	
TRIPLE-NEGATIVE	BREAST	CANCER	
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Advisory	Professor:	Mien-Chie	Hung,	Ph.D.	
											The	Yes-associated	protein	 (YAP)	 is	an	effector	 that	 transduces	 the	output	of	the	 Hippo	 pathway	 to	 transcriptional	modulation.	 Considering	 the	 role	 of	 YAP	 in	cancers,	this	protein	has	emerged	as	a	key	node	in	malignancy	development.	In	this	study,	 we	 determined	 that	 Aurora	 A	 kinase	 acts	 as	 a	 positive	 regulator	 for	 YAP-mediated	 transcriptional	 machinery.	 Specifically,	 YAP	 associates	 with	 Aurora	 A	predominantly	 in	 the	nucleus.	Activation	of	Aurora	A	 can	 impinge	on	YAP	activity	through	direct	phosphorylation.	Moreover,	aberrant	expression	of	YAP	and	Aurora	A	 signaling	 is	 highly	 correlated	 with	 triple-negative	 breast	 cancer	 (TNBC).	 We	herein	 provide	 evidence	 to	 establish	 the	 functional	 relevance	 of	 this	 newly	discovered	 regulatory	 axis	 in	 TNBC.	 This	 study	 not	 only	 has	 advanced	 the	understanding	 of	 the	 intricate	 network	 of	 YAP	 in	 cancers	 but	 also	 has	 revealed	 a	potential	route	to	intervene	oncogenic	YAP	function.			
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CHAPTER	1	
INTRODUCTION														
	 2	
1.1:	Overview	of	Breast	Cancers	Breast	 cancer	 is	 the	 most	 frequent	 cancers	 in	 U.S.	 women	 population	 with	estimated	 230,000	 new	 cases	 and	 40,000	 deaths	 in	 2015	 (1).	 	 Types	 of	 breast	cancers	 can	 be	 classified	 depending	 on	 histopathological	 origins	 of	 the	 disease,	including	 ductal	 carcinoma,	 lobular	 carcinoma	 and	 inflammatory	 breast	 cancer.	Among	them,	ductal	carcinoma	is	the	most	commonly	found.	There	are	several	risk	factors	 associated	 with	 the	 onset	 of	 breast	 cancers;	 however,	 at	 this	 moment,	hereditary	 BRCA1/2	 gene	 mutation	 represents	 the	 most	 predictive	 markers	 for	breast	cancer.		The	stages	and	types	of	cancers	determine	treatments	of	breast	cancer.	There	are	 four	major	 routes	 of	 treatments,	 including	 surgical	 removal	 of	 part	 or	 whole	breast	(mastectomy),	radiation	therapy,	chemotherapy,	hormone	therapy	and	target	therapy.	 Usually	 the	 treatment	 procedure	 would	 combine	 at	 least	 two	 of	abovementioned	options	(Information	was	obtained	from	National	Cancer	Institute;	http://www.cancer.gov/types/breast/patient/breast-treatment-pdq).		Hormone	 receptors	 play	 key	 roles	 to	 stimulate	 and	 maintain	 breast	 cancer	growth.	Once	a	breast	cancer	is	diagnosed,	the	cancer	cells	are	closely	examined	for	their	molecular	signatures	based	on	the	protein	expression	or	gene	amplification	of	estrogen	 receptor	 (ER),	 progesterone	 receptor	 (PR)	 or	 ERBB2	 (HER2/neu).	 After	the	 examination	 of	 these	 three	 markers,	 breast	 cancers	 are	 classified	 as	 ER/PR-positive	but	HER2-negative,	HER2-positive	(Lumina	A	subtype	with	ER/PR-positive;	
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Luminal	 B	 with	 ER/PR-negative)	 and	 triple-negative	 breast	 cancer	 (TNBC;	ER/PR/HER2-negative)	(2).		In	addition	to	surgery,	radiation	and	systemic	chemotherapies,	breast	cancer	with	 specific	 expression	 of	 receptor	 receives	 corresponding	 treatment	 to	 block	hormone	 effect.	 This	 procedure	 is	 called	 hormone	 ablation	 or	 endocrine	 therapy.	Tamoxifen	and	aromatase	inhibitors	are	used	to	block	action	of	ER	or	to	lower	down	the	 production	 of	 estrogen.	 HER2-positive	 patients	 would	 receive	 anti-HER2	therapy	such	as	monoclonal	antibody	(Herceptin;	chemical	name:	trastuzumab)	and	small	molecular	compounds	(i.e.	Lapatanib)	that	inhibit	HER2.		The	discovery	of	hormone	ablation	therapies	has	greatly	advances	the	survival	rate	of	breast	cancer	patients.	In	general,	around	60-70%	of	ER-positive	and	HER2-positive	patients	will	 respond	to	anti-estrogen	or	anti-HER2	therapy.	According	 to	the	statistics	conducted	from	2005	to	2011	by	Surveillance,	Epidemiology,	and	End	Results	 Program	 (SEER)	 at	 National	 Cancer	 Institute,	 the	 current	 overall	 5-year	survival	rate	of	breast	cancer	reaches	89.4%.	Although	overall	breast	cancer	is	more	manageable	than	many	other	cancer	types,	to	eliminate	breast	cancer	is	still	the	final	goal	 as	 each	 year	 there	 are	 still	 nearly	 40,000	 lives	 in	 US	 deceased	 from	 it.	Particularly,	triple-negative	breast	cancer	(TNBC)	is	a	subtype	of	breast	cancers	that	currently	lacks	effective	treatments	and	the	overall	survival	of	TNBC	is	worst	among	all	 breast	 cancers.	 Identification	of	 the	 cause	of	 aggressiveness	 and	 the	 targetable	targets	represents	an	urgent	challenge	for	breast	cancer	research	field.	
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1.2:	Background	of	Triple-Negative	Breast	Cancer	(TNBC)	In	general,	TNBC	is	more	aggressive	and	has	a	poor	prognosis	compared	to	ER-positive	breast	 cancers,	 regardless	of	 the	 stages	when	cancers	were	diagnosed	 (3,	4).	Among	 total	 new	breast	 cancer	patients	 diagnosed,	 around	15-20%	are	TNBC.	Due	 to	 the	 lack	 of	 expression	 of	 ER,	 PR	 and	 HER2,	 TNBC	 does	 not	 respond	 to	endocrine	or	anti-HER2	therapy.	TNBC	has	higher	recurrence	rate	within	the	first	5-year	after	treatment	and	the	recurrent	TNBC	is	hardly	manageable.		TNBC	 shares	 a	 common	 morphological	 and	 genetic	 status	 with	 basal-like	breast	cancer	(BLBC).	BLBC	is	a	subtype	of	breast	cancers	defined	by	a	unique	gene	profile.	Usually	BLBC	expresses	basal	cytokeratin	5,	14	and	17.	Around	70%	TNBC	can	 be	 classified	 as	 BLBC	 (5).	 The	 rest	 30%	 of	 TNBC	 is	 consisted	 of	 unclassified	subtypes	 with	 different	 gene	 expression	 profiles,	 indicating	 TNBC	 should	 be	considered	as	a	complex	type	of	disease.			Though	 recurrent	 TNBC	 is	 hardly	manageable,	 chemotherapy	 is	 effective	 as	first	line	treatment	for	TNBC.	In	general,	TNBC	responds	well	to	antracycline-based	and	 taxane-based	 therapies	 (6,	 7).	 Alternative	 treatments	 for	 TNBC	 may	 include	EGFR	 inhibitors,	 Src	 inhibitors	and	poly-ADP-ribose	polymerase	 (PARP)	 inhibitors	that	are	currently	under	clinical	trials.	EFGR	is	expressed	in	up	to	70%	of	TNBC	(8-10).	 Clinical	 trial	 data	 so	 far	 shows	 low	 efficacy	 when	 anti-EGFR	 monoclonal	antibody,	Cetuximab,	was	used	alone.	However,	in	a	small	study	enrolled	18	patients	
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with	 metastatic	 TNBC,	 5	 patients	 showed	 a	 complete	 or	 partial	 response	 to	 the	combination	of	taxane	with	cetuximab	(11).			As	mentioned	earlier,	BRCA1/2	gene	mutation	represents	the	most	predictive	genetic	 marker	 for	 breast	 cancers.	 Most	 breast	 cancers	 associated	 with	 BRCA	mutation	 fall	 into	 TNBC	 and	 BLBC.	 However,	 the	 relationship	 between	 BRCA	mutation	and	 the	onset	of	TNBC	or	BLBC	 is	 still	unclear.	BRCA	and	PARP	are	 two	major	 pathways	 that	 maintain	 a	 functional	 DNA	 repair	 system.	 In	 BRCA-mutant	cancers,	 PARP	becomes	 essential	 to	maintain	 sufficient	DNA	 repair	machinery	 for	the	cell	survival.	Therefore,	the	combination	of	PARP	inhibitors	with	DNA-damaging	drugs	 (for	 example,	 platinum-based	 compounds)	 has	 shown	 promising	 results	 in	BRCA-mutant	ovarian	cancer.	The	encouraging	results	have	led	to	an	approval	from	FDA	 (Food	 and	 Drug	 Administration)	 to	 use	 Lynparza,	 a	 PARP	 inhibitor,	 in	 the	treatment	of	advanced	ovarian	cancer	with	defective	BRCA	genes.	Similar	trials	are	ongoing	in	TNBC	patients	and	the	results	are	encouraging	thus	far.			
1.3:	Hippo	Pathway-	Discovery	and	Overview	The	Hippo	pathway	was	discovered	to	regulate	the	organ	size	by	the	screening	of	mutant	Drosophila	melanogaster.	Mutation	of	a	kinase	induced	the	outgrowth	of	target	 organs	 and	 the	 phenotype	 is	 like	 hippopotamus,	 therefore	 this	 kinase	was	named	 “hpo”	 (12-14).	 Later	 discoveries	 have	 supported	 a	 solid	 role	 of	 Hippo	pathway	 in	 the	 regulation	 of	 tissue	 homeostasis,	 apoptosis,	 proliferation	 and	
	 6	
environmental	 mechanosensing	 (15,	 16).	 Very	 similar	 to	 other	 canonical	 signal	pathways	 in	 the	 cells,	 the	Hippo	 pathway	 consists	 of	 two	major	 serine/threonine	kinases	(Hpo	and	Wts	in	fly;	MST1/2	and	LATS1/2	in	mammals)	in	the	cascade	(15,	16).	The	major	role	of	these	two	kinases	is	to	sense	environmental	or	cellular	cues	and	transduce	them	to	the	most	downstream	effectors	that	control	expression	of	a	variety	of	genes.	Hippo	pathway	is	quite	conserved	from	fly	to	mammals.	The	major	difference	 is	 that,	 in	 fly,	 there	 is	only	one	downstream	effector	called	Yorkie	 (Yki)	while	in	mammals,	there	are	two	paralogue	effectors,	named	Yes-associated	protein	(YAP)	 and	 transcriptional	 co-activator	 with	 PDZ-binding	 motif	 (TAZ	 or	 WWTR1)	(15,	16).	Hereafter	we	will	mainly	focus	on	the	mammalian	Hippo	pathway.														
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Figure	1.3:	Illustration	of	the	Mammalian	Hippo	Pathway																		Reproduced	with	 permission	 from	 Johnson	 R,	 Halder	 G.	 2014.	 The	 two	 faces	 of	Hippo:	 targeting	 the	 Hippo	 pathway	 for	 regenerative	 medicine	 and	 cancer	treatment.	Nat	Rev	Drug	Discov	13:63-79.			
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1.4:	Regulators	of	the	Hippo	Pathway	Hippo	pathway	translates	the	signal	output	from	membrane	to	the	nucleus	by	inhibiting	YAP	and	TAZ	activity.	Unlike	other	signaling	pathways,	there	are	no	ligand	or	 peptide	 that	 can	 directly	 activate	 Hippo	 cascade.	 Instead,	 Hippo	 pathway	 can	sense	 the	 activity	 from	 cell-cell	 junction,	 cell-matrix	 junction	 and	 cytoskeleton	dynamics	(15).	Upon	the	activation	of	Hippo	pathway,	MST1/2	kinase	(mammalian	STE20-like	 protein	 kinase)	 phosphorylates	 and	 activates	 LATS1/2	 kinase	 (large	tumor	 suppressor	homolog).	 Two	major	proteins	 SAV1	 (Salvador	homolog	1)	 and	MOB1A/B	(Mps	One	Binder	Kinase	Activator-Like)	serve	as	scaffolding	proteins	to	support	 and	 bridge	 function	 of	 MST-LATS	 axis.	 LATS1/2	 kinase	 subsequently	phosphorylates	 YAP	 and	 TAZ	 protein.	 After	 YAP	 and	 TAZ	 protein	 are	phosphorylated	by	Hippo	pathway,	 their	 localization	 is	 switched	 to	 the	 cytoplasm	and	therefore	the	transcriptional	activity	is	shut	off.	The	more	detailed	mechanisms	of	 how	MST,	 LATS	 kinases	 and	 YAP/TAZ	 are	 regulated	 by	 upstream	modules	 are	described	below.		
1.5:	From	Environmental	Cues	to	the	Hippo	Pathway	Activation	 of	 MST	 and	 LATS	 pathway	 can	 attribute	 to	 four	 major	 types	 of	signals:	 Cell	 polarity	 complex,	 direct	 regulators	 of	 MST	 or	 LATS	 kinase	 from	 cell	junctions,	 stiffness	 of	 cell-extracellular	 matrix	 (ECM)	 attachment	 and	 cell-cell	contact.	 Several	 of	 these	 signalings	 more	 or	 less	 affect	 Hippo	 pathway	 through	affecting	organization	of	cytoskeleton.		
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Cell	polarity	complex	regulates	Hippo	pathway.	Crumb	protein	complex	(CRB)	is	critical	to	define	apical	phase	of	a	cell	(17).	CRB	is	a	transmembrane	protein	with	a	short	intracellular	domain	that	serves	as	protein	docking	platform.	CRB	has	been	shown	 to	 regulate	 Hippo	 pathway	 (18-22).	 For	 example,	 CRB	 complex	 recruits	angiomotin,	a	cell	junction	protein,	to	the	apical	membrane	(22)	and	angiomotin	can	affect	 Hippo	 pathway	 by	 two	 ways.	 One	 is	 to	 directly	 bind	 with	 YAP	 and	 thus	 it	restricts	 YAP	 to	 the	 membrane;	 the	 other	 is	 to	 interact	 with	 and	 activate	 LATS	kinase,	 therefore	 it	 induces	YAP	nuclear	export	 (23-27).	Although	angiomotin	was	shown	 to	 cause	 inhibition	 of	 YAP	 activity,	 however,	 in	 an	 angiomotin-knockout	mouse	cancer	model,	angiomotin	appears	to	be	essential	for	transactivation	activity	of	YAP	in	the	nucleus	(28).	It	appears	angiomotin	may	possess	positive	and	negative	effects	on	YAP	activity	in	a	cell-context-dependent	manner.		KIBRA	(kidney	and	brain	protein)	and	TAO	kinase	(thousand	and	one	amino	acid	protein)	are	apical	junction	proteins	that	influence	Hippo	pathway.	Association	with	KIBRA	promotes	Hippo	pathway	to	restrict	cell	growth	(29-32).	TAO	is	a	cell-junction	kinase	downstream	of	KIBRA.	It	can	directly	phosphorylate,	activate	LATS	kinase	and	thus	inhibit	YAP-mediated	cell	growth	(33-35).				Mechanical	 force	was	 recently	 found	 to	 regulate	Hippo	 pathway,	 linking	 the	mechanical	 sensing	 of	 cells	 to	 signal	 transduction.	 Stiffness	 of	 cell-extracellular	matrix	(ECM)	attachment	was	indicated	to	influence	Hippo	pathway.	Briefly,	a	softer	matrix	can	activate	Hippo	pathway	and	make	YAP	shuttle	to	the	cytoplasm;	while	a	
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stiff	matrix	can	promote	nuclear	import	of	YAP	that	stimulates	cell	proliferation	(36-38).	F-actin	dynamics	controls	the	mechanosignaling	to	YAP	and	TAZ	(38).			Although	 there	 is	 no	 clearly	 defined	 receptor	 that	 directly	 influences	 Hippo	pathway,	 some	 G	 protein-coupled	 receptors	 (GPCRs)	 were	 discovered	 to	 activate	YAP	and	TAZ	through	the	actin	reorganization.	GPCR	stimulators	like	lysophatic	acid	(LPA)	and	sphigosine-1-phosphate	(S1P)	were	shown	to	inhibit	Hippo	pathway	(39-41).	 	High	 confluence	of	 cell-cell	 contact	 also	 activates	Hippo	pathway	 and	moves	YAP,	TAZ	to	the	cytoplasm	(42).	Although	the	detail	mechanism	is	still	unclear,	it	is	possible	 that	 high	 cell	 density	 engages	 complex	 formation	 of	 junctional	 proteins	such	 as	 CRB,	 PATJ,	 PALS,	 E-cadherin,	 alpha-catenin	 and	 angiomotin,	 which	 were	shown	to	directly	or	indirectly	promote	nuclear	export	of	YAP	and	TAZ	(43-46).			
1.6:	Effectors	of	the	Hippo	Pathway	-	Discovery,	Structural	Features,	Working	
Mechanisms		The	most	downstream	effectors	of	the	Hippo	pathway	are	transcriptional	co-activators,	YAP	and	TAZ,	which	 transduce	upstream	signals	 to	gene	expression.	 In	flies,	mutation	of	the	Hippo	kinase	induces	abnormal	enlargement	of	target	organs,	and	this	phenotype	is	rescued	by	deletion	of	Yki	(Yorkie,	YAP	orthologue	in	fly)	(12-14).	In	humans,	YAP	and	the	PDZ-binding	protein,	TAZ,	are	the	two	paralogues	that	seem	to	have	a	redundant	role	 in	 terms	of	Hippo	signaling	(16).	The	 full	 length	of	
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YAP	 protein	 contains	 504	 amino	 acids.	 Structurally,	 YAP	 protein	 contains	 a	transcriptional	 factor-binding	 domain	 in	 its	 N-terminal	 half	 and	 one	 to	 two	WW	domains	depending	on	which	isoforms.	The	C-terminus	of	WW	domains	is	followed	by	 the	 transactivation	 domain	 (TD).	 The	 last	 five	 amino	 acids	 of	 YAP	 protein	comprise	 a	 PDZ-binding	motif	 (PDZ-bm).	WW	domain	 is	 composed	 by	 around	 40	amino	acids	 that	direct	 the	binding	of	YAP	with	PPxY	motif	on	other	proteins.	For	example,	YAP	interacts	with	LATS	kinase	and	angiomotin	through	the	WW	domain	(26,	47).	Transactivation	domain	of	YAP	protein	is	used	to	turn	on	the	expression	of	the	 downstream	 genes.	 PDZ-binding	 motif	 can	 interact	 with	 protein	 with	 PDZ	domains.	 PDZ-domain	 containing	 proteins	 are	 usually	 found	 to	 help	 anchor	receptors	 to	 the	 membrane	 and	 supporting	 cytoskeleton.	 Of	 note,	 though	 PDZ-binding	motif	of	YAP	protein	only	consists	of	five	amino	acids,	it	was	reported	PDZ-bm	 is	 very	 critical	 for	 the	 nuclear	 localization	 and	 transactivation	 activity	 of	 YAP	(48).	 	YAP	protein	itself	does	not	contain	a	DNA-binding	domain.	In	order	to	achieve	the	activity	on	gene	regulation,	YAP	interacts	with	numerous	transcriptional	factors	that	possess	DNA-binding	ability.	Plenty	of	works	have	demonstrated	that	YAP	can	exert	 its	 transactivation	effect	by	 interacting	with	TEADs	 (TEA	domain-containing	sequence-specific	 transcription	 factor),	 p73,	 beta-catenin,	 Smad,	 TBX5,	 c-fos	 (49-55).		 	
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Although	 the	 determinants	 that	 decide	 the	 association	 of	 YAP	 with	 other	specific	protein	partners	are	yet	to	be	investigated,	the	interaction	between	YAP	and	these	DNA-binding	factors	at	least	reflects	a	complex	role	of	YAP	in	various	cellular	scenarios.	 Among	 YAP-interacting	 DNA-binding	 proteins,	 TEADs	 are	 the	 major	accomplice	 for	 YAP’s	 function	 as	 a	 transcriptional	 co-factor	 (52).	 It	 was	 revealed	that	mutation	of	the	TEAD-binding	motif	on	YAP	at	serine	94	severely	compromised	its	 biological	 output	 (52).	 Also,	 through	 systematic	 chromatin-IP	 sequencing	analyses,	 several	 studies	 revealed	 that	 the	 occupancy	 of	 TEADs	 highly	 coincides	with	YAP-binding	genes,	corroborating	the	role	of	TEADs	in	YAP’s	function	(52,	56).		
1.7:	YAP	and	TAZ	–	Phenotypes	in	Developmental	Stages		YAP	and	TAZ	play	key	roles	 in	embryonic	development	of	mice.	Whole	body	knockout	 (KO)	of	 YAP	 causes	 embryo	death	between	E9.5	 to	E10.5.	Differentially,	whole	body	knockout	of	TAZ	reduces	litter	size,	body	size	and	it	only	causes	partial	postnatal	 death	 or	 prematuration.	 This	 suggests	 that	 YAP	 and	 TAZ	 play	 different	roles	 in	 the	 development,	 though	 structurally	 they	 are	 similar.	 Besides	 the	phenotypes	observed	from	the	whole	body	knockout	experiment,	there	were	plenty	of	 works	 indicate	 the	 key	 roles	 of	 YAP	 and	 TAZ	 in	 the	 development	 of	 different	specific	 organs,	 including	 liver,	 pancreas,	 salivary	 glands,	 kidney,	 lung,	 heart,	intestine,	skin	and	nervous	system	(57).	Of	note,	it	is	not	just	the	expression	level	of	YAP	and	TAZ	controls	the	development,	the	subcellular	localization	of	YAP	and	TAZ	appears	more	important.		
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1.8:	Regulation	of	YAP	and	TAZ	So	far,	the	major	control	that	regulates	YAP	activity	is	through	modulating	its	subcellular	localization.	YAP	protein	is	shuttled	between	the	nucleus	and	cytoplasm	in	 a	well-controlled	manner.	 YAP	 activity	 is	 largely	 regulated	 by	 upstream	Hippo	kinases.	 In	humans,	MST1/2	and	LATS1/2	consist	of	a	central	kinase	cascade	that,	upon	activation,	inhibits	YAP	activity	by	direct	phosphorylation	on	multiple	sites	of	the	YAP	protein	(14,	42,	58).	Upon	phosphorylation	from	the	LATS	kinase	on	serine	127	of	YAP,	YAP	is	sequestered	by	14-3-3	to	the	cytoplasm,	and	the	transcriptional	program	in	the	nucleus	is	subsequently	shut	off	(14,	42).	Furthermore,	LATS	kinase	phosphorylation	 of	 YAP	 on	 serine	 397	 has	 been	 shown	 to	 decrease	 YAP	 stability	(59).	LATS	phosphorylation	of	YAP	primes	YAP	for	a	sequential	phosphorylation	on	amino	 acids	 401	 and	 403	 by	 CK1	 kinase	 and	 this	 eventually	 leads	 to	 beta-TrCP–directed	proteasomal	destruction	in	the	cytoplasm	(59).	In	addition	to	the	negative	regulatory	 circuit	 from	 the	 Hippo	 pathway,	 YAP	 can	 be	 inactivated	 by	 a	 direct	sequestration	to	the	cytoplasm	from	angiomotin	(an	F-actin-binding	protein	located	in	 cell	 junctions)	 and	 alpha-catenin	 (23,	 25,	 26,	 44,	 45,	 60).	 In	 general,	 most	 of	studies	 have	 identified	 signaling	 that	 negatively	 regulates	 YAP	 function;	 however,	signaling	and	mechanisms	that	directly	elevate	YAP	transcriptional	activity	remain	less	characterized.		In	the	nucleus,	YAP	acts	as	a	transcriptional	co-factor	and	it	has	been	reported	to	 promote	 expression	 of	 several	 growth-related	 genes,	 for	 example,	CTGF,	Birc5,	
Amphiregulin,	Cyr61,	and	EGFR	 (16,	61).	Although	the	very	determinant	genes	that	
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directly	influence	cell	proliferation	are	yet	to	be	investigated,	several	other	studies	have	 shown	 that	 DNA	 replication	 proteins,	 MCM	 family	 and	 cell	 cycle-regulating	genes	may	be	downstream	genes	of	YAP	(62-65).		
1.9:	Relevance	of	the	Hippo	Pathway	in	Cancers		The	 relevance	 of	 YAP	 and	 TAZ	 in	 cancer	 development	 has	 been	 widely	reported	 (16).	Dysregulation	of	YAP	expression	has	been	 shown	 in	 several	 cancer	types,	for	example,	in	breast,	ovarian,	lung,	pancreatic,	liver,	colorectal	cancers	and	in	malignant	mesothelioma	and	medulloblastomas	(66-68).	In	experimental	models,	YAP	 was	 reported	 to	 mediate	 tumorigenesis,	 anti-apoptosis,	 drug	 resistance,	 and	metastatic	programing	(16,	69-71).	For	example,	overexpression	of	YAP	in	the	liver	causes	 liver	 enlargement	 and	 hepatocellular	 carcinoma	 in	mice,	 proving	 a	 strong	oncogenic	 property	 of	 YAP	 in	 vivo	 (72,	 73).	 In	 these	 studies,	 short-term	overexpression	 of	 YAP	 in	 the	 liver	 can	 obviously	 increase	 the	 liver	 size	 in	 a	reversible	 manner;	 however,	 a	 long-term	 expression	 of	 YAP	 leads	 to	 a	 dramatic	formation	 of	 liver	 cancer.	 Expression	 of	 YAP	 reduces	 anoikis	 and	 promotes	chemoresistance	 in	 cancer	 cells	 (74).	 In	 melanoma,	 YAP	 promotes	 resistance	 to	BRAF	 and	 MEK1/2	 inhibitors	 (75).	 YAP	 and	 TAZ	 can	 facilitate	 epithelial-mesenchymal	 transition	 (EMT),	 increase	 cancer	metastasis,	 and	 endow	 cells	 with	cancer-initiating	 properties	 (52,	 55,	 76-79).	 Furthermore,	 YAP	 has	 been	 shown	crucial	for	Kras-induced	PDAC	development	(80).	Expression	of	YAP	is	sufficient	to	alleviate	 the	 dependence	 of	 Kras	 in	 a	 PDAC	mouse	model	 (63).	 These	 expanding	reports	support	an	intriguing	role	of	YAP	in	cancer	biology.	
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1.10:	Aurora	A	Kinase	-	Discovery	and	Structure	Aurora	 family	 kinases	were	 discovered	 first	 in	 yeast	where	mutation	 of	 Ip1	(increase-in-ploidy)	 causes	 the	 failure	 in	 normal	 chromosome	 segregation	 (81).	Later	 findings	 in	Xenopus	and	 fly	all	 revealed	crucial	roles	of	Aurora	kinase	 in	 the	mitotic	 control	 (82-84).	 The	 phenotypes	 of	 Aurora	 kinase	 deficiency	 in	 model	systems	were	similar.	For	example,	in	fly,	the	mutation	of	Aurora	A	kinase	is	coupled	with	pupal	lethality,	mitotic	arrest,	defect	in	centrosome	segregation	and	the	loss	of	spindle	polarity	(85-88).			
1.11:	 Regulation	of	Aurora	A	Kinase	Structurally,	Aurora	A	 is	 consisted	of	 403	 amino	 acids.	 The	 canonical	 kinase	domain	 is	nearby	within	amino	acids	133	to	383.	Regarding	the	activity	control	of	Aurora	 A,	 the	 amino	 acids	 274	 to	 299	 are	 so-called	 “mobile	 loop”,	 whose	conformational	change	will	determine	the	kinase	active	or	not.	 In	the	mobile	 loop,	the	threonine	288	residue	represents	the	most	well-studied	and	critical	site	for	the	kinase	 activity.	 Threonine	 288	 is	 an	 auto-phosphorylation	 site	 and	 its	phosphorylation	can	be	promoted	by	the	interaction	of	Aurora	A	kinase	with	other	co-activators	 (discussed	 below).	 In	 addition	 to	 be	 auto-phosphorylated,	 threonine	288	or	residue	287	can	be	a	direct	substrate	for	PAK,	protein	kinase	A	and	atypical	protein	kinase	C.			Although	 several	 kinases	 have	 been	 shown	 to	 direct	 phosphorylate	 on	threonine	 288	 of	 Aurora	 A	 kinase	 and	 therefore	 activate	 Aurora	 A	 activity,	 the	
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binding	of	specific	protein	co-activators	with	Aurora	A	controls	the	major	enzymatic	output	of	Aurora	A.	Aurora	A	kinase	belongs	to	the	AGC	family	of	kinases	(PKA,	PKG,	PKC	families)	and,	unlike	receptor	tyrosine	kinases	(RTKs),	its	activation	is	achieved	by	 interacting	 with	 specific	 protein	 co-factors.	 Activation	 of	 Aurora	 A	 kinase	 has	been	 reported	 to	 attribute	 to	 the	 interaction	 with	 TPX2	 (Targeting	 Protein	 for	XKLP),	Nedd9,	Ajuba,	Bora,	Calmodulin	 and	PAK1	 (89).	TPX2	 represents	 the	most	well-characterized	allosteric	 activator	 for	Aurora	A.	 	Upon	binding	with	Aurora	A,	TPX2	induces	a	conformational	change	in	Aurora	A	toward	its	active	state,	and	this	substantially	 elevates	 its	 kinase	 activity	 (90,	 91).	 Intermolecular	autophosphorylation	 occurs	 on	 Thr288	 of	 Aurora	 A	 and	 then	 further	 pushes	 its	maximum	kinase	activity	 (92,	93).	 It	was	nicely	demonstrated	 in	a	comprehensive	structural	 study	 that	 binding	 of	 TPX2	 and	 phosphorylation	 of	 Aurora	 A-T288	 can	independently	elevate	Aurora	A	kinase	activity	(94).		
1.12:	 Roles	of	Aurora	A	in	The	Cell	Cycle	Control	In	human,	there	are	three	family	members	of	Aurora	kinase,	Aurora	A,	B	and	C.	Aruroa	A	and	B	regulate	general	mitosis	and	Aurora	C	kinase	regulates	meiosis	(95).	Since	Aurora	A	is	more	relevant	to	cancers	and	is	our	focus	in	this	research,	we	will	mainly	focus	on	the	role	of	Aurora	A	hereafter.			Aurora	A	is	pivotal	in	the	regulation	of	cell	cycle	progression,	particularly	for	the	 G2-M	 phase	 transition.	 Mutation	 of	 Aurora	 A	 kinase	 renders	 a	 multi-aspect	defect	in	chromosome	segregation	resulted	from	inaccurate	number	of	centrosomes	
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and	mis-positioning	of	mitotic	spindles	(89).	In	non-transform	cells,	the	mRNA	level	of	Aurora	A	starts	to	accumulate	in	the	S-phase	and	then	peaks	at	G2/M	phase	(96).	Accumulated	Aurora	A	protein	begins	to	concentrate	on	centrosomes	and	they	help	increase	 the	 diameter	 of	 centrosomes	 by	 nucleating	 relevant	 tubulins	 and	 other	protein	 complexes,	 like	 PCM	 (pericentriolar	 mass)	 (97).	 Once	 the	 mitosis	 is	completed,	Aurora	A	protein	is	subjected	to	the	proteasomal	degradation	mediated	by	 APC/C	 (anaphase-promoting	 complex)	 (98).	 The	 phosphorylation	 of	 serine	 51	residue	of	human	Aurora	A	seems	to	control	this	degradation	process.	Expression	of	PP2A	(phosphatase	2A)	that	removes	phosphorylation	of	serine	51	can	decrease	the	degradation	of	Aurora	A	in	late	mitosis	(91,	99).		Activation	 of	 Aurora	 A	 kinase	 during	 G2/M	 cell	 cycle	 is	 largely	 induced	 by	TPX2.	TPX2	 is	a	nuclear	protein	and	 it	 is	 released	upon	 the	breakdown	of	nuclear	envelope.	The	released	TPX2	therefore	not	only	begins	to	assemble	spindles	but	also	binds	with	Aurora	A	for	kinase	activation	(100-104).	Once	Aurora	A	is	activated,	it	phosphorylated	 its	 own	 threonine	 288	 to	 further	 potentiate	 kinase	 activity	 and	 it	also	 phosphorylates	 surrounding	 centrosome	 complex,	 including	 TPX2,	 PLK1	kinase,	LATS	kinase.	Overall	the	phosphorylation	event	coming	from	Aurora	A	helps	the	maturation	of	centrosome,	spindle	assembly/positioning	and	ignites	the	mitotic	entry.	Aurora	A	activates	CDK1/cyclin	B	around	the	centrosome	and	this	facilitates	of	 the	 nuclear	 import	 of	 CDK1/	 cyclin	 B	 that	 can	 promote	 cell	 cycle	 progression	(105,	106).	Also,	the	Aurora	A	downstream	PLK1	kinase	can	further	phosphorylate	on	WEE1,	a	CDK1/cyclin	B	 inhibitor,	 to	decrease	 the	 inhibitory	effect	of	WEE1	on	
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CDK1,	 therefore	 the	CDK1/cyclin	B	 activity	 can	 sustain	during	 the	 cell	 cycle	 (107,	108).	In	the	end	of	G2	phase,	Aurora	A	directly	phosphorylates	CDC25B,	an	activator	of	CDK	at	mitosis,	to	promote	M	phase	entry	(109).	Interestingly,	Aurora	A	can	also	phosphorylate	BRCA1	 at	 the	 serine	 308	 and	 this	 event	 somehow	 is	 important	 for	transitioning	G2	to	M	phase	(110,	111).	The	downstream	event	of	BRCA1	in	this	case	is	still	not	clear.		
1.13:	 Relevance	of	Aurora	A	in	Cancers	Genome	instability	is	a	hallmark	of	cancers.	Abnormal	expression	or	activation	of	Aurora	A	causes	aneuploidy	(112).	Aurora	A	 is	highly	expressed	or	amplified	 in	breast,	colon,	skin,	ovary,	head	and	neck	cancers	 (112-116).	Besides	 its	roles	of	 in	the	cell	 cycle,	Aurora	A	has	been	shown	 to	affect	various	other	cellular	behaviors,	including	cell	signaling	(117,	118),	migration/metastasis	(119-122),	drug	resistance	(123-126),	 and	 stem	 cell	 properties	 (125,	 127,	 128).	 Aurora	 A	 kinase	 is	 highly	relevant	in	human	cancers	because	its	expression	and	gene	amplification	correlate	with	malignant	 phenotypes	 in	 cancers	 (95,	 129).	 Aberrant	 activation	 of	 Aurora	 A	increases	 chromosomal	 instability	 (CIN)	 in	 cells	 (130).	 However,	 one	 reports	indicated	that	Aurora	A	may	exert	oncogenic	functions	independent	of	CIN	(131).		
1.14:	Aurora	A	Substrates	and	Its	Non-Mitotic	Roles	In	 addition	 to	 those	 kinase	 substrates	 in	 mitotic	 regulation,	 expanding	discoveries	 have	 shown	 that	 Aurora	 A	 also	 phosphorylates	 numerous	 substrates	(more	than	22)	participating	in	various	cellular	functions	(89).	For	example,	Aurora	
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A	 phosphorylates	 p53	 and	 induces	 degradation	 of	 p53	 protein	 (132).	 Also,	 it	 can	phosphorylate	p73	and	this	leads	to	the	cytoplasmic	retention	of	p73	(133).	Aurora	A	phosphorylates	AP-2apha,	a	tumor	suppressor,	and	induce	AP-2alpha	degradation	(134).	Phosphorylation	of	IkB-alpha,	inhibitor	of	NF-kB	pathway,	by	Aurora	A	leads	to	 the	destruction	of	 IKB-alpha	and	elevates	NF-kB	signaling	 (117,	135).	Aurora	A	also	 involves	 in	 cell	 signaling.	 For	 example,	 it	 phosphorylates	 AKT	 and	RALA	 and	this	consequently	increases	the	activation	of	AKT	and	Ras	activity	(124,	136,	137).			
1.15:		 Aurora	A	Kinase	As	A	Cancer	Target	Owing	 to	 the	 oncogenic	 role	 of	 Aurora	 A	 kinase	 supported	 by	 a	 wealth	 of	studies,	considering	Aurora	A	kinase	as	a	therapeutic	target	is	of	intensive	interest	in	cancer	treatment.	According	the	information	from	the	ClinicalTrials.gov,	to	date,	there	 are	 26	 ongoing	 cancer	 clinical	 trials	 using	 the	 Aurora	 A	 inhibitor,	 Alisertib	(MLN8237),	alone	or	in	combination	with	other	drugs.	Many	more	trials	have	been	completed	 in	 the	 past	 5	 years.	 Thus	 far,	 only	 limited	 partial	 responses	 have	 been	observed	 from	 the	 clinical	 trials,	 therefore	 the	 identification	 of	 biomarkers	 or	resistant	 mechanisms	 may	 greatly	 help	 guide	 the	 use	 of	 Aurora	 A	 inhibitors,	assuming	Aurora	A	is	still	a	promising	target	in	cancers.						
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1.16:		 Rationale	and	Hypothesis	Functional	studies	of	the	pathogenesis	of	TNBC	are	emerging	topics	in	breast	cancer	research.	The	discoveries	of	key	genes	critical	 for	TNBC	growth	or	survival	may	help	reveal	the	TNBC	vulnerability	and	overall	this	direction	is	in	hope	to	bring	out	targeting	therapeutics	in	the	future.	We	have	identified	that	the	Hippo	pathway	effector,	YAP,	is	critical	to	support	TNBC	cell	growth	in	the	three-dimensional	(3D)	culture	condition.	However,	it	is	still	not	clear	how	other	targetable	pathways	might	involve	in	YAP	function	in	TNBC.	We	hypothesized	that	there	are	oncogenic	kinases	that	 can	 directly	 enhance	 YAP	 activity.	 In	 this	 study,	 we	 utilized	 proteomic	approach,	bioinformatics	analysis	and	in	vitro	functional	characterization	to	provide	a	better	understanding	on	YAP,	seeking	to	provide	an	alternative	way	for	managing	the	oncogenic	role	of	YAP	in	TNBC.												
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CHAPTER	2	
RESULTS												
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2.1:	Expression	of	YAP	Correlates	with	TNBC		
2.1.1:	mRNA	Expression	of	YAP	from	the	Public	Databases	Although	higher	YAP	expression	(protein	and/or	mRNA)	has	been	correlated	with	malignant	 phenotypes	 in	many	 other	 cancer	 types,	 the	 correlation	 of	 YAP	 in	breast	 cancer	 subtypes	 in	 not	 clear.	 To	 address	 whether	 there	 is	 a	 differential	expression	of	YAP	in	breast	cancer	types,	especially	in	TNBC,	we	analyzed	the	mRNA	expression	 level	of	YAP	 from	public	databases	of	both	patients	 (TCGA,	The	Cancer	Genome	 Atlas)	 and	 cell	 lines	 (CCLE,	 Cancer	 Cell	 Line	 Encyclopedia)	 by	 a	 simple	bioinformatics	 analysis.	 From	 the	 results,	 YAP	 expression	 significantly	 associates	with	the	TNBC	subtype	(Figures	2.1.1A	and	B)	both	in	patients	(n	=	296;	P	=	7.93E-9)	and	in	cell	lines	(n	=	58).													
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Figure	2.1.1	 Expression	of	YAP	mRNA	Correlates	with	TNBC	A	
	B	
		(A) Heatmap	analysis	of	mRNA	expression	of	YAP	and	breast	cancer	markers	in	TCGA	database	(analyzed	by	Oncomine®	platform).	(B) Heatmap	analysis	of	mRNA	expression	of	YAP	and	breast	cancer	markers	in	CCLE	database	(analyzed	by	GENE-E	platform).						
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2.1.2:	 Protein	Expression	of	YAP	in	Cell	Lines	Since	 the	 mRNA	 expression	 of	 YAP	 is	 significantly	 correlated	 with	 TNBC	subtypes	 from	 the	 public	 databases.	We	wonder	 if	 the	 protein	 level	 of	 YAP	 has	 a	similar	trend	of	expression	in	TNBC.	To	test	this,	we	selected	a	panel	of	commonly	used	cell	 lines	 in	 the	 lab,	 containing	 five	TNBC	and	 five	non-TNBC	cells	 to	explore	the	protein	expression	level	of	YAP.	Interestingly,	TNBC	cell	lines	in	general	express	higher	amount	of	YAP	protein	in	immunoblotting	(Figure	2.1.2).																		
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Figure	2.1.2:	Expression	of	YAP	Protein	Correlates	with	TNBC		 											Immunoblot	assay	to	detect	YAP	expression	in	a	panel	of	breast	cancer	cell	lines.										
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2.1.3:	Knockdown	of	YAP	Reduces	3D	Cell	Growth	Knowing	that	both	the	mRNA	and	protein	expression	level	of	YAP	are	indeed	more	profound	 in	TNBC	subtypes,	 the	biological	role	of	YAP	 in	 terms	of	TNBC	cell	growth	 is	not	 clear.	 It	 is	 of	 our	 interest	 to	know	whether	YAP	plays	 an	oncogenic	role	in	TNBC	or	not.	To	answer	this	question,	we	used	three	TNBC	cells	(MDA-MB-231,	MDA-MB-468	 and	 Hs578T)	 for	 the	manipulation	 of	 YAP	 expression	 level	 by	short	 interference	 RNAs	 (siRNAs)	 or	 CRISPR-cas9	 knockout	 system	 and	 then	monitored	 the	 cell	 growth.	 Several	 stable	YAP-knockdown	 (KD)	or	knockout	 (KO)	cell	 lines	 were	 established.	 However,	 from	 the	 results,	 we	 did	 not	 observe	 a	noticeable	growth	difference	of	 these	stable	cell	 lines	 in	 the	two-dimensional	(2D)	colony-formation	assay.	Since	it	is	generally	believed	in	the	cancer	field	that	three-dimensional	(3D)	cell	culture	can	better	mimic	tumor	growth	properties	in	vitro,	we	then	 tested	 the	 growth	 of	 these	 stable	 clones	 on	 either	 matrigel	 or	 soft	 agar.	Interestingly,	we	 found	 that	 in	 all	 three	 cell	 lines,	 knockdown	or	knockout	of	YAP	expression	has	 significantly	 reduced	 the	number	of	 colonies	 formed	 in	3D	 culture	condition	(Figures	2.1.3.1	to	2.1.3.4).	Reconstituting	the	expression	of	YAP	in	YAP-KO	 cells	 rescues	 the	 cell	 growth	on	matrigel	 (Figure	2.1.3.4	C).	 The	quantification	results	 of	 soft	 agar	 assay	 were	 shown	 in	 Figure	 2.1.3.5.	 Overall,	 these	 lines	 of	evidence	suggest	that	YAP	plays	an	oncogenic	role	in	TNBC	cell	growth.						
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Figure	2.1.3.1:	Knockdown	of	YAP	Does	Not	Affect	2D	Cell	Growth	in	MDA-MB-
231	cells		A								B									(A) Immunoblot	of	YAP	to	show	shRNA	efficiency	in	MDA-MB-231	cells.	(B) Colony	growth	of	MDA-MB-231	cells	knocked	down	with	YAP	shRNAs	in	2D	culture.	Scm,	scrambled	shRNA	control.		
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Figure	2.1.3.2:	Knockdown	of	YAP	Does	Not	Affect	2D	Cell	Growth	 in	Hs578T	
Cells	A						
B												 (A) Immunoblot	of	YAP	to	show	shRNA	efficiency	in	Hs578T	cells.	(B) Colony	growth	of	Hs578	cells	knocked	down	with	YAP	shRNAs	in	2D	and	soft	agar	culture.	
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Figure	2.1.3.3:	Knockdown	of	YAP	Does	Not	Affect	2D	Cell	Growth	in	MDA-MB-
468	Cells	 	A							B										 (A) Immunoblot	of	YAP	to	show	shRNA	efficiency	in	MDA-MB-468	cells.	(B) Colony	growth	of	MDA-MB-468	cells	knocked	down	with	YAP	shRNAs	in	2D	and	soft	agar	culture.		
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Figure	2.1.3.4:	Knockout	of	YAP	Reduces	3D	Cell	Growth	A	 	 	 	 B		
			 	 			
	 	 	 	 	 C							(A) Immunoblot	of	YAP	and	CTGF	in	MDA-MB-231	YAP-KO	cells.	(B) Colony	 growth	 of	MDA-MB-231	 YAP-knockout	 (YAP-KO)	 cells	 in	 soft	 agar	culture.	(C) Images	 of	 MDA-MB-231	 cell	 growth	 on	 matrigel.	 KO	 indicates	 knockout.	Control,	CRISPR-sgRNA	targeting	EGFP.	(Scale	bar	is	200	μm)	
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Figure	2.1.3.5:	Quantification	of	3D	Cell	Growth	from	Three	TNBC	Lines	
		Quantification	of	visible	colony	numbers	in	soft	agar	assays.	Error	bars	indicate	the	SD	(n=3).	*P	<	0.05,	Student’s	t-test.												
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2.2:	Aurora	A	Kinase	Interacts	with	YAP	
2.2.1:	Identification	of	YAP-Interacting	Proteins	by	a	Proteomic	Approach	Since	the	oncogenic	role	of	YAP	in	terms	of	supporting	the	cell	growth	in	TNBC	has	 been	 determined,	 next	 we	 would	 like	 to	 know	 how	 YAP	 activity	 may	 be	regulated	by	other	 interacting	proteins.	To	 tackle	 this	 task,	we	 first	need	 to	know	what	are	other	proteins	that	show	physical	interaction	with	YAP	in	TNBC	cells.	We	took	advantage	of	the	tandem-affinity-purification	system	(TAP)	and	coupled	it	with	mass	spectrometry	analysis	(M/S)	for	the	identification	of	YAP-interacting	proteins.	TAP	system	 is	good	 for	 identification	of	protein-protein	 interaction	as	 this	 system	uses	 double	 affinity-elution	 process	 to	 reduce	 most	 of	 the	 nonspecific	 binding	 ,	compared	to	the	regular	immunoprecipitation	method.	First,	we	constructed	a	TAP-YAP-expressing	 lentiviral	 vector	 (with	 protein	 A	 and	 calmodulin-binding	 domain	tags).	Then	we	established	a	stable	clone	of	TAP-YAP	in	MDA-MB-231	cells.	Using	a	stable	clone	 for	protein	purification	 is	beneficial,	as	a	 long-term	expression	of	bait	protein	would	allow	the	bait	protein	to	restore	the	stoichiometric	ratio	with	other	endogenous	proteins.	We	then	purified	the	YAP-interacting	protein	complexes	from	a	 huge	 amount	 of	 protein	 lysates	 under	 a	 non-denaturing	 condition.	 The	 eluted	proteins	 were	 separated	 by	 SDS-PAGE	 and	 stained	 by	 coomassie	 blue	 on	 the	 gel	(Figure	2.2.1.1).	 	In	the	figure,	a	strong	band,	which	corresponds	to	the	size	of	YAP	was	shown,	indicating	a	successful	purification.			The	 eluted	 protein	 complexes	 were	 subjected	 to	 M/S	 analysis	 through	 a	collaboration	 laboratory	 located	in	Taiwan.	A	total	of	184	unique	protein	IDs	have	
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been	 identified	 through	M/S.	We	 then	 input	 the	protein	 list	 to	 Ingenuity	Pathway	Analysis	 (IPA;	 from	Qiagene)	platform	to	analyze	 the	association	of	 these	proteins	with	 cellular	 signaling	 pathways.	 As	 expected,	 21	 of	 184	 proteins	 have	 been	reported	 to	 relate	 to	 Hippo	 pathway.	 38	 of	 184	 proteins	 have	 been	 reported	 to	interact	with	YAP	 (Figure	2.2.1.2).	These	 results	have	 indicated	 the	 faithfulness	of	our	 purification	 system	 and	 condition	 that	 can	 well	 preserve	 YAP-associated	complexes.																			
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Figure	2.2.1.1:	Pull-Down	of	YAP	Complex																Coomassie	 blue	 staining	 of	 the	 pulled-down	 elution	 of	 MDA-MB-231	 stable	 cells.	TAP	 indicates	 a	 no-bait	 control	 (Tandem-affinity-purification	 tag	 only).	 TAP-YAP,	YAP1	protein	N-terminus-tagged	of	TAP	sequence.					
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Figure	2.2.1.2:	Network	of	YAP-Interacting	Proteins	from	M/S	
	Interaction	map	of	YAP-associated	protein	complexes	from	our	study.	Only	proteins	reported	with	direct	interaction	with	YAP	were	shown.	Green	color	indicates	those	reported	in	the	Hippo	pathway.	Arrows	indicate	the	kinase/substrate	relationship.	The	results	were	analyzed	and	drawn	by	the	IPA®	platform.			
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2.2.2:	Clinical	Relevance	of	AXL,	CIT	and	Aurora	A	kinases	in	Breast	Cancers	From	the	newly	 identified	YAP-associated	proteins	 in	MDA-MB-231	cells,	we	found	three	kinases,	which	were	not	reported	in	the	literatures.	These	three	kinases	are	Aurora	A	kinase,	CIT	kinase	 (Citron	Rho-Interacting	Serine/Threonine	Kinase)	and	AXL	tyrosine	kinase.	Kinases	are	particularly	of	our	research	 interest	as	 there	are	many	small	compound	inhibitors	readily	available	and	many	of	them	are	now	in	clinical	trials.	Identification	of	kinase	that	regulates	YAP	activity	may	decipher	a	new	use	 from	 existing	 drugs	 to	 control	 YAP	 activity.	 In	 order	 to	 select	 kinases	 more	relevant	 to	 the	malignancy	of	breast	cancer,	we	analyzed	 the	patient	survival	data	based	on	the	mRNA	expression	level	of	these	three	kinases.	We	used	an	online	tool,	Kaplan	Meier	plotter	(138),	 to	 find	the	correlation	 in	3,554	breast	cancer	patients.	From	the	results,	only	the	expression	of	Aurora	A	correlates	with	a	poor	prognosis	in	 overall	 breast	 cancers	 (Figure	 2.2.2	 A).	 This	 result	 prompted	 us	 to	 focus	 on	investigating	 further	 of	 potential	 regulation	 of	 Aurora	 A	 on	 YAP	 protein.	Interestingly,	 after	 analyzing	 the	 expression	 correlation	 of	 Aurora	 A	 and	 its	activator,	 TPX2,	 from	 a	 TCGA	 breast	 cancer	 database,	 we	 also	 observed	 a	 nice	correlation	of	Aurora	A	with	TNBC	subtype	(Figure	2.2.2	B).	These	results	suggests	Aurora	A	and	TPX2	are	relevant	to	TNBC.						
	 37	
Figure	2.2.2:	Clinical	Relevance	of	Identified	Kinases	in	Breast	Cancers		A	
		B	
		(A) Analysis	 of	 the	 correlation	of	 kinases	 and	breast	 cancer	patient	 survival	 in	Kaplan	Meier	plotter	(http://kmplot.com/analysis/).	(B) Heatmap	analysis	of	mRNA	expression	of	TPX2,	Aurora	A,	and	breast	cancer	markers	in	TCGA	database	(analyzed	by	Oncomine®	platform).				
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2.2.3:	Aurora	A	kinase	Physically	Interacts	with	YAP	The	presence	of	Aurora	A	kinase	in	the	YAP-containing	complex	encouraged	us	to	further	validate	whether	Aurora	A	indeed	can	interact	with	YAP	protein.	First,	we	used	 immunoblot	 to	check	 if	Aurora	A	was	 indeed	 in	 the	sample	subjected	to	M/S	analysis.	From	the	result,	we	can	clearly	see	that	Aurora	A	was	found	in	the	sample	(Figure	2.2.3	A).	Then	we	tested	whether	YAP	can	interact	with	endogenous	Aurora	A	in	cells.	MDA-MB-231	and	H1299	cells	were	tested	by	immunoprecipitation	assay	to	pull	down	YAP	and	 immunoblotted	Aurora	A.	From	the	result,	YAP	can	 interact	with	 Aurora	 A	 (Figure	 2.2.3	 B).	 Furthermore,	 in	 order	 to	 detect	 where	 the	interaction	 between	 Aurora	 A	 and	 YAP	 occurs	 inside	 the	 cells,	 we	 performed	 a	proximity-ligation	 assay	 in	 MDA-MB-231	 cells.	 Interestingly,	 the	 majority	 of	interaction	happened	in	the	nucleus	(Figure	2.2.3	C).													
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Figure	2.2.3:	Aurora	A	kinase	Interacts	with	YAP		A							B							C						
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Figure	2.2.3:	Aurora	A	kinase	Interacts	with	YAP	(A) Immunoblot	of	Aurora	A	in	elution	from	(Figure	2.2.2.2).	(B) Co-immunoprecipitation	 of	 YAP	 and	 Aurora	 A	 protein	 from	 two	 different	cells.	(C) Proximity	 ligation	 assay	 to	 analyze	 co-localization	 of	 YAP	 and	 Aurora	 A	 in	MDA-MB-231	cells.	The	scale	bar	represents	10	μm.																		
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2.3:	Aurora	A	Kinase	Regulates	YAP-Mediated	Transcriptional	Activity	
2.3.1:	Inhibition	of	Aurora	A	Decreases	CTGF	Expression	As	YAP	functions	as	a	transcriptional	co-activator	in	the	nucleus	and	Aurora	A	happens	to	interact	with	YAP	in	the	nucleus	(Figure	2.2.3	C),	we	hypothesized	that	Aurora	 A	 may	 affect	 the	 transcriptional	 activity	 of	 YAP.	 To	 quickly	 tested	 this	possibility,	we	 treated	an	Aurora	A	kinase	 inhibitor,	MLN8237,	 in	 two	TNBC	cells,	MDA-MB-231	 and	 Hs578T,	 to	 see	 if	 it	 has	 any	 effect	 on	 YAP	 target	 gene,	 CTGF.	Interestingly,	upon	the	 inhibition	of	Aurora	A	kinase	activity,	 the	CTGF	expression	level	went	down	(Figure	2.3.1.1	A).	Examination	of	mRNA	expression	of	CTGF	also	indicated	a	downregulation	by	Aurora	A	inhibitor	(Figure	2.3.1.1	B).		Chemical	inhibitors	may	possess	off-target	effects.	To	consolidate	our	findings	that	 Aurora	 A	 is	 required	 for	 YAP-mediated	 CTGF	 expression,	we	 used	 siRNAs	 to	test	 the	 hypothesis	 again.	 In	Hs578T	 cells,	 knockdown	 of	 Aurora	 A	 decreases	 the	expression	of	CTGF	(Figure	2.3.1.2	A).	Similarly,	knockout	of	Aurora	A	by	CRISPR-cas9	 system	 in	 MDA-MB-231	 cells	 also	 decrease	 the	 expression	 of	 CTGF	 (Figure	2.3.1.2	B).	These	results	suggested	that	Aurora	A	kinase	is	required	for	optimal	YAP	transcriptional	activity.						
	 42	
Figure	2.3.1.1:	Aurora	A	Inhibitor	Reduces	Expression	of	CTGF	A								B										(A) Immunoblot	 of	CTGF	expression	 from	 lysates	of	MDA-MB-231	and	Hs578T	cells	treated	with	or	without	Aurora	A	kinase	inhibitor,	MLN8237.	(B) RT-qPCR	analysis	of	CTGF	mRNA	level	from	MDA-MB-231	and	MDA-MB-231-TPX2	cells	treated	with	MLN8237.	
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Figure	2.3.1.2:	Knockdown	of	Aurora	A	Reduces	Expression	of	CTGF		A								B									(A) Immunoblot	 of	 CTGF	 expression	 in	 Hs578	 cells	 transfected	 with	 siRNAs	against	Aurora	A.	(AA,	Aurora	A)	(B) Immunoblot	 of	 CTGF	 expression	 in	 MDA-MB-231-Aurora	 A-KO	 cells.	 (KO,	knockout)	
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2.3.2:	Activation	of	Aurora	A	Increases	Expression	of	YAP-Target	Gene	Activation	 of	 Aurora	 A	 is	 demonstrated	 by	 monitoring	 the	 phosphorylation	status	of	 its	own	threonine	288	(T288)	residue.	However,	when	we	overexpressed	Aurora	 A	 alone,	 it	 did	 not	 cause	 an	 activation	 of	 Aurora	 A	 (Figure	 2.3.2.1).	 To	efficiently	activate	Aurora	A,	we	chose	to	stimulate	Aurora	A	activity	by	expressing	TPX2,	a	strong	co-activator	of	Aurora	A.	Indeed,	expression	of	TPX2	induces	a	robust	activation	of	Aurora	kinase,	supported	by	the	auto-phosphorylation	at	T288	(Figure	2.3.2.1).	Because	of	 this	 result,	we	 later	only	used	exogenously	expressed	TPX2	 to	serve	as	a	stimulus	for	Aurora	A	activity.				We	wonder	whether	activation	of	Aurora	A	signaling	can	increase	YAP	activity.	To	test	this	hypothesis,	we	established	a	stable	TPX2-expressing	MDA-MB-231	line	and	used	 immunoblotting	 to	detect	 the	expression	 level	of	YAP-target	gene,	CTGF.	From	the	results,	 it	 shows	 that	expression	of	TPX2	 is	 sufficient	 to	 induce	a	higher	expression	of	CTGF,	compared	to	the	vector	control.	Similar	to	the	result	in	section	2.3.1,	 inhibition	 of	 Aurora	 A	 by	 kinase	 inhibitor	 or	 siRNAs	 has	 also	 diminished	TPX2-induced	CTGF	in	both	mRNA	and	protein	level,	suggesting	that	TPX2	induces	CTGF	level	through	Aurora	A	(Figure	2.3.2.2	A	and	B;	Figure	2.3.1.1	B).	These	results	demonstrated	that	Aurora	A	can	positively	regulate	YAP	activity.					
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Figure	2.3.2.1:	TPX2	Activates	Aurora	A	Kinase	Activity																Immunoblot	assay	 to	detect	 the	activation	of	Aurora	A	 from	 lysates	of	 transfected	293T	cells.						
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Figure	2.3.2.2:	Activation	of	Aurora	A	Induces	Expression	of	CTGF	A									B								(A) Immunoblot	 of	 CTGF	 expression	 from	 MDA-MB-231	 cells	 with	 stable	expression	 of	 FLAG-TPX2.	 Cells	 were	 treated	 with/without	 MLN8237	 and	collected	at	indicated	time	point.	(F:TPX2,	FLAG-TPX2)	(B) Immunoblot	 of	 CTGF	 level	 in	MDA-MB-231-TPX2	 cells	 knocked	down	with	siRNAs	against	Aurora	A	(AA).	
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2.3.3:	Aurora	A	Potentiates	YAP-Regulated	Promoter	Activity	To	 further	delineate	whether	Aurora	A	can	directly	affect	 the	 transcriptional	activity	of	YAP,	we	used	a	luciferase	reporter	system	to	test	the	activity	of	YAP.	The	reporter	system	contains	three	functional	elements,	including	an	activator,	a	GAL4-containg	 DNA-binding	 protein	 and	 a	 UAS-driven	 luciferase	 reporter.	 How	 does	 it	work?	 For	 example,	 when	 YAP	 is	 expressed	 with	 GAL4-TEAD	 in	 the	 presence	 of	UAS-luciferase	reporter,	YAP	will	 complex	with	TEAD	and	the	YAP/TEAD	complex	will	 specifically	 bind	 on	UAS	 sequence	due	 to	GAL4.	 If	 the	 binding	protein	 on	 the	UAS	possesses	activity	toward	transcriptional	regulation,	the	luciferase	gene	will	be	expressed	and	the	result	can	be	quantified	biochemically.			From	 our	 result,	 expression	 of	 YAP	 can	 induce	 TEAD-dependent	 promoter	activation	 in	 about	 30	 folds	 compared	 to	 the	 control	 (Figure	2.3.3).	 Expression	 of	YAP	or	TEAD	alone	was	not	sufficient	to	activate	the	reporter,	indicating	this	system	has	 very	 low	 background	 in	 cells	 tested.	 Interestingly,	 co-expression	 of	 Aurora	A/TPX2	can	further	potentiate	YAP	activity	to	around	60	folds	more	than	controls.	Expression	 of	 a	 kinase-dead	 mutant	 of	 Aurora	 A	 losses	 this	 potentiation	 of	 YAP	activity,	suggesting	the	kinase	activity	of	Aurora	A	is	an	essential	 factor	to	activate	YAP	(Figure	2.3.3).						
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	Figure	2.3.3:	Aurora	A	Activates	YAP-Mediated	Transcription																			Luciferase	 reporter	 assay	 to	 evaluate	 activity	 of	 YAP	 under	 the	 influence	 of	 TPX2	plus	Aurora	A	(AA).	AA-KD	represents	a	kinase-dead	mutant	(K162R)	of	Aurora	A.	Error	bars	indicates	the	SD	(n	=	3).	*P	<	0.05,	Student’s	t-test.		
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2.4:	YAP	Is	A	Novel	Substrate	of	Aurora	A	Kinase	
2.4.1:	Aurora	A	Phosphorylates	YAP	in	vitro	Since	Aurora	A	not	only	 interacts	with	YAP	 in	 the	nucleus	but	 also	activates	YAP’s	 transcriptional	activity,	we	wondered	 if	Aurora	A	can	serve	as	a	kinase	 that	directly	 phosphorylates	 YAP	 protein.	 To	 test	 this	 possibility,	 we	 performed	 an	 in	
vitro	 kinase	 assay	 by	 using	 recombinant	Aurora	A	 kinase	 and	YAP	protein.	 In	 the	presence	 of	 gamma-p32-ATP,	 we	 can	 observe	 a	 strong	 phosphorylation	 event	 on	YAP.	Adding	the	Aurora	A	kinase	inhibitor	in	the	reaction	completely	abolished	the	phosphorylation	 on	 YAP	 (Figure	 2.4.1).	 This	 result	 demonstrated,	 in	 vitro,	 YAP	protein	can	be	a	substrate	of	Aurora	A	kinase.	This	was	a	novel	discovery	related	to	YAP	regulation.													
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Figure	2.4.1:	Aurora	A	Kinase	Phosphorylates	YAP	in	vitro	
		
In	vitro	kinase	assay	using	p32-ATP.	Recombinant	Aurora	A	kinase	and	GST-tagged	YAP	proteins	are	used.	(AAi:	Aurora	A	inhibitor)					
	 51	
2.4.2:	Protein	Domains	of	YAP	Phosphorylated	by	Aurora	A	Since	Aurora	A	can	phosphorylate	the	full-length	YAP	protein,	next	we	would	like	to	 identify	which	specific	domains	of	YAP	are	responsible	 for	phosphorylation	coming	from	Aurora	A.	Again,	we	performed	an	 in	vitro	kinase	assay	using	several	truncated	 protein	 fragments	 of	 YAP	 protein	 (schematic	 presentation	 of	 protein	domains	are	 listed	 in	Figure	2.4.2	A).	The	results	 showed	 that	only	 the	C-terminal	half	(amino	acids	270-504)	can	be	phosphorylated	by	Aurora	A.	Further	dissection	showed	that	amino	acids	371-410	is	indispensible	for	phosphorylation.	Deletion	of	amino	 acids	 371-410	 has	 lost	 majority	 of	 phosphorylation	 signal	 from	 Aurora	 A,	suggesting	 this	 small	 area	 may	 contain	 the	 important	 resides	 for	 the	phosphorylation	event.													
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Figure	2.4.2:	Protein	Domains	of	YAP	Phosphorylated	by	Aurora	A	Kinase	A						B										(A) Schematic	 illustration	 of	 different	 YAP	 fragments	 used	 in	 (E).	 Labeled	 part	represents	a	potential	region	that	contributes	to	the	phosphorylation	signal.	(+)	and	(–)	represent	whether	the	protein	fragments	was	phosphorylated	or	not,	respectively	from	(C).	(B) In	vitro	kinase	assay	to	evaluate	the	phosphorylation	status	of	truncated	YAP	proteins.	
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2.4.3:	Identification	of	The	Phosphorylation	Site	of	YAP	Knowing	that	protein	domain	encompassing	amino	acids	371	to	410	of	YAP	is	the	critical	area	to	receive	phosphorylation	from	Aurora	A	kinase,	next	we	sought	to	identify	whether	 there	 is	 a	 critical	 serine	 or	 threonine	 residue	 for	 this	 event.	We	combined	 several	 criteria,	 including	 our	 experimental	 results,	 known	 Aurora	 A	consensus	substrate	sequence,	our	own	M/S	analysis	and	M/S	results	from	a	public	database	 (Phosphosites;	 Cell	 SignalingTM)	 to	 narrow	 down	 the	 candidates.	 By	overlapping	these	criteria	together,	only	the	serine	397	residue	is	a	candidate	that	fits.	We	performed	an	 in	vitro	 kinase	assay	using	YAP	protein	mutated	 its	S397	 to	alanine	 as	 the	 substrate.	 Interestingly,	 mutation	 of	 S397	 has	 lost	 most	 of	 the	phosphorylation	 signal	 from	 Aurora	 A	 (Figure	 2.4.3).	 Furthermore,	 using	 a	commercially	 available	 monoclonal	 antibody	 which	 recognizes	 YAP-S397	phosphorylation,	we	can	also	detect	a	specific	signal	from	the	reaction	of	the	in	vitro	kinase	assay.	The	antibody	cannot	detect	the	signal	when	S397	site	was	mutated	to	alanine	(Figure	2.4.3).	These	results	suggested	that	serine	397	of	YAP	is	the	major	site	to	be	phosphorylated	by	Aurora	A	kinase.								
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Figure	2.4.3:	YAP-S397	Is	A	Aurora	A	Phosphorylation	Site												Immunoblot	 and	 in	 vitro	 kinase	 assay	 to	 evaluate	 the	 phosphorylation	 status	 of	Serine	397	of	YAP	protein	(YAP-S397)	in	the	presence	of	Aurora	A	kinase.	His-YAP	represents	a	 recombinant	 fragment	of	His-tagged	YAP	protein	 (a.a.	271-504).	WT:	wild-type;	S397A:	alanine	mutant.								
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2.4.4:	Endogenous	YAP	Is	Phosphorylated	by	Aurora	A	Although	YAP	is	a	substrate	of	Aurora	A	kinase	in	test	tubes,	we	wonder	if	the	cellular	endogenous	phosphorylation	of	S397	of	YAP	can	be	influenced	by	Aurora	A.	To	 test	 this	 notion,	 endogenous	 Aurora	 A	was	 knocked	 down	 by	 siRNAs	 in	 three	TNBC	 cell	 lines,	 MDA-MB-231,	 Hs578T	 and	 MDA-MB-468.	 As	 we	 expected,	knockdown	of	Aurora	A	significantly	reduces	the	phosphorylation	of	YAP-S397	site	(Figure	 2.4.4.1).	 In	 contrast,	 expression	 of	 TPX2	 to	 activate	 endogenous	Aurora	A	increases	 the	 phosphorylation	 of	 YAP-S397	 in	 MDA-MB-231	 and	 BT-549	 cells	(Figure	2.4.4.2	A	and	B).	The	phosphorylation	signal	detected	by	the	antibody	was	specific	as	mutation	of	YAP-S397	to	alanine	lost	the	signal	(Figure	2.4.4.2	B).																
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Figure	2.4.4.1:	Phosphorylation	of	YAP-S397	Is	Regulated	by	Aurora	A	in	vivo											Evaluation	of	phosphorylation	of	YAP-S397	by	immunoblot	in	cells	knocked	down	of	Aurora	A	(AA).											
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Figure	2.4.4.2:	Activation	of	Aurora	A	Increase	Phosphorylation	of	YAP-S397		A							B								(A) Immunoblot	 of	 YAP-S397	 phosphorylation	 from	 lysate	 of	 MDA-MB-231-TPX2	cells.	(B) Immunoblot	 to	 evaluate	 the	 level	 of	 YAP-S397	 phosphorylation	 in	 the	presence	of	TPX2	or	not.			
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2.4.5:	Cell	Cycle-Dependent	Phosphorylation	of	YAP		One	of	 the	major	physiological	regulations	of	Aurora	A	activity/expression	 is	the	cell	cycle.	We	wondered	if	physiology-relevant	activation	of	Aurora	A	can	induce	the	phosphorylation	of	YAP-S397.	To	test	this	question,	we	used	double-thymidine	block	 to	 synchronize	 the	 cell	 cycle	of	Hs578T	 cells.	After	 released,	 the	 cell	 lysates	were	collected	following	a	time	course.	Expressions	of	cyclin	B1	and	cyclin	E	were	used	as	markers	to	show	the	status	of	the	cell	cycle.	From	the	result	(Figure	2.4.5),	cell	 cycle	 was	 indeed	 synchronized	 at	 G1/S	 boundary	 and	 then	 it	 gradually	progressed	 into	 G2	 and	 M	 phase,	 as	 indicated	 by	 the	 expression	 pattern	 of	corresponding	cyclin(s).	Expression	of	Aurora	A	peaked	at	G2/M	phase	as	reported	in	the	literatures.	Interestingly,	phosphorylation	of	YAP-S397	peaked	mostly	at	the	same	 time	point	with	Aurora	A.	 This	 result	 strongly	 supported	 that	Aurora	A	 can	phosphorylate	YAP	on	S397	site	and	this	might	postulate	that	the	activity	of	YAP	can	be	regulated	through	a	cell-cycle-dependent	manner.												
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Figure	2.4.5:	Cell-Cycle	Dependent	Phosphorylation	of	YAP-S397																Immunoblot	of	phospho-YAP-S397	in	Hs578T	cells	that	are	cell	cycle	synchronized	by	double-thymidine	block.						
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2.5:	Phosphorylation	of	YAP	by	Aurora	A	Occurs	Predominantly	in	the	Nucleus	
2.5.1:	TPX2	Induces	YAP	Phosphorylation	Mainly	in	the	Nucleus	Since	 YAP	 and	 Aurora	 A	 predominantly	 interacts	 with	 each	 other	 in	 the	nuclear	compartment,	we	wonder	if	the	phosphorylation	of	YAP-S397	occurs	mostly	in	 the	 nucleus.	 To	 test	 this,	we	 transiently	 transfected	 TPX2-expressing	 construct	into	MDA-MB-231	cells	and	performed	an	immunofluorescent	staining	on	YAP-S397	phosphorylation.	 From	 the	 result,	 the	 phosphorylation	 signal	 of	 YAP-S397	 indeed	mainly	 localized	 in	the	nucleus	of	TPX2-transfected	cells	(Figure	2.5.1	A).	Through	cell	 fractionation	 assay	 to	 separate	 nuclear	 and	 cytoplasmic	 proteins,	we	 can	 also	observed	that	in	TPX-2	stable	cells,	YAP-S397	phosphorylation	occurs	mainly	in	the	nucleus	(Figure	2.5.1	B).	Hippo-LATS	kinase	was	shown	to	phosphorylate	the	same	site	 in	 the	cytoplasm.	Our	 finding	suggests	 that	 the	regulation	of	YAP-S397	site	by	Aurora	 A	 is	 spatially	 distinct	 from	 LATS	 regulation	 (detail	 discussion	 is	 in	 the	Discussion	section).											
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Figure	2.5.1:	Aurora	A	Induces	Phosphorylation	of	YAP-S397	in	the	Nucleus	A							B															
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Figure	2.5.1:	Aurora	A	Induces	Phosphorylation	of	YAP-S397	in	the	Nucleus		(A) Immunoblot	 of	 YAP-S397	 phosphorylation	 in	 subcellular	 extracts	 of	 MDA-MB-231	cells,	in	the	presence	of	TPX2	or	not.	N.N.E.,	non-nuclear	extract;	N.E.	nuclear	extracts.		(B) Confocal	microscopy	analysis	of	YAP-S397	phosphorylation	in	MDA-MB-231	cells	transfected	with	FLAG-TPX2	plasmids.	For	FLAG	antibody,	Alexa	®	594	secondary	antibody	(red)	was	used;	for	YAP-S397p,	Alexa	®	488	secondary	antibody	(green)	was	used.															
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2.5.2:	Clinical	Correlation	of	YAP	Phosphorylation	with	TPX2	To	 understand	 whether	 Aurora	 A-mediated	 phosphorylation	 of	 YAP-S397	occurs	 in	 patient	 samples,	 TNBC	 tissue	 microarrays	 were	 used	 for	immunohistochemistry	staining	to	detect	the	expression	level	of	TPX2	and	phospho-YAP.	 TPX2	was	 used	 as	 a	marker	 because	TPX2	 represents	 the	 activity	 control	 of	Aurora	A.	Aurora	A	expression	itself	does	not	guarantee	the	activity.	From	the	IHC	result	 performed	 by	 a	 pathologist,	 Dr.	 Weiya	 Xia,	 we	 do	 see	 a	 nice	 correlation	between	expression	of	TPX2	and	phospho-YAP	from	a	total	of	114	patient	samples	(p=0.0001)	(Figure	2.5.2	A	and	B).	These	results	suggested	that	activation	of	Aurora	A	has	a	significant	contribution	to	the	phosphorylation	of	YAP-S397	site.														
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Figure	 2.5.2:	 Expression	 of	 TPX2	 Correlates	 with	 Phospho-YAP	 in	 Patient	
Samples		A							B	
  Expression of TPX2		 	 – /+	 ++	 +++  	 Total	 P value	
Phospho-Yap	 – /+	 19 (67.9%)	 9 (40.9%)	 15 (23.4%)	 43 (37.7%)	 		 ++	 2 (7.1%)	 9 (40.9%)	 12 (18.8%)	 23 (20.2%)	 		 +++  	 7 (25%)	 4 (18.2%)	 37 (57.8%)	 48 (42.1%)	 		 Total	 28 (100%)	 22 (100%)	 64 (100%)	 114 (100%)	 P = 0.0001*										
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Figure	 2.5.2:	 Expression	 of	 TPX2	 Correlates	 with	 Phospho-YAP	 in	 Patient	
Samples		 (A) Representative	images	of	immunohistochemistry	staining	from	specimens	of	breast	cancer	patients.	Antibodies	against	human	TPX2	or	YAP-S397p	were	used.	(B) Relationships	between	TPX2	and	phospho-YAP-S397	expression	 in	surgical	specimens	of	triple-negative	breast	cancer.	*Correlation	between	TPX2	and	phospho-YAP-S397	was	analyzed	by	using	the	Pearson	Chi-Square	test	(P	<	0.0001).	 A	 P	 value	 of	 <	 0.05	 was	 set	 as	 the	 criterion	 for	 statistical	significance.	Thank	Dr.	Weiya	Xia	for	performing	and	grading	the	results.													
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2.6:	Dependence	of	Aurora	A	Kinase	Activity	for	YAP-Mediated	Transforming	
Ability	
2.6.1:	Aurora	A	Increases	3D	Colony	Formation	We	have	demonstrated	in	earlier	results	that	Aurora	A	kinase	can	regulate	the	transcriptional	activity	of	YAP.	However,	until	now,	whether	Aurora	A	can	influence	YAP-mediated	 biological	 function	 is	 still	 unclear.	 Regarding	 cell	 growth,	 YAP	was	only	critical	in	the	3D	culture	condition.	So	we	then	tested	the	effect	of	Aurora	A	on	YAP-mediated	 cell	 growth	 in	 the	 soft	 agar	 assay.	 From	 the	 results,	 expression	 of	YAP-WT	(wild-type)	or	YAP-S127A	 (a	 constitutively	active	 form	of	YAP	which	has	lost	 the	 inhibitory	 regulation	 from	 Hippo	 pathway)	 in	 BT-549	 cells	 increases	 the	colony	 growth.	 Interestingly,	 Co-expression	 of	 TPX2	 in	 these	 cells	 can	 further	increase	the	colony	numbers	to	around	3	folds	more	(Figure	2.6.1	A).	Similarly,	in	a	non-transformed	 mouse	 fibroblast	 cell	 line,	 NIH-3T3,	 co-expression	 of	 TPX2	 can	potentiate	the	colony-forming	numbers	mediated	by	both	YAP-WT	and	YAP-S127A	(Figure	2.6.1	B).	These	results	indicated	that	functionally	Aurora	A	kinase	serves	as	an	enhancer	to	boost	YAP-induced	biological	phenotypes.								
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Figure	2.6.1:	Activation	of	Aurora	A	Enhances	Transforming	Ability	of	YAP					A	 	 	 	 	 	 						B	
	 	 	 	 	 	 					(A) Colony	growth	of	BT-549	cells	in	soft	agar	assay	(18	days	after	plating).	BT-549	cells	were	manipulated	to	stably	co-express	wild-type	YAP	(YAP-WT)	or	S	 to	A	mutant	of	YAP-S127	 (YAP-S127A)	and	FLAG-TPX2.	Quantified	 result	(n=3)	of	visible	colonies	is	shown.	(B) Same	as	(A)	but	NIH-3T3	cells	were	used	in	the	assay.			
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2.6.2:	YAP-S397	Is	Required	for	TPX2-Mediated	Activity	and	Transformation	Does	Aurora	A-mediated	 YAP	 function	 go	 through	 the	 serine	 397	 residue	 of	YAP?	As	we	have	 identified	 that	S397	 is	 the	major	site	 to	receive	phosphorylation	from	Aurora	A,	we	wondered	if	this	phosphorylation	event	accounts	for	the	Aurora	A	 and	 YAP-mediated	 biological	 output.	 To	 test	 this,	we	 used	 a	 luciferase	 reporter	assay	and	a	soft	agar	assay	to	examine	the	possible	importance	of	serine	397	of	YAP.	From	 the	 soft	 agar	 assay,	 the	 result	 indicated	 that	 activation	 of	 Aurora	 A	 can	 no	longer	 enhance	 the	 colony-forming	ability	mediated	by	YAP,	when	 its	 S397	 site	 is	mutated	to	alanine	(Figure	2.6.2	A).	Similarly	in	the	reporter	assay,	mutation	of	YAP-S397	 to	 alanine	 also	 greatly	 reduces	 the	 responsiveness	 to	 Aurora	 A-directed	potentiation	 (Figure	 2.6.2	 B).	 These	 results	 suggests	 that	 serine	 397	 of	 YAP	 is	functionally	important	and	Aurora	A	kinase	regulates	this	site.														
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Figure	2.6.2:	YAP-S397	Is	Critical	for	Aurora	A-Mediated	Activity	A	 	 	 	 	 	 	 B	
	 	 	 	 	 		 	 	 	(A) Similar	to	(Figure	2.6.1	A),	but	cells	expressing	YAP-S397A	was	assayed	and	quantified.	(B) Luciferase	 reporter	 assay	 (system	 is	 same	 as	 Figure	 3G)	 to	 evaluate	 the	transcriptional	activity	of	YAP-WT	or	YAP-S397A.	Error	bars	indicate	the	SD.	*	P	<	0.05,	Student’s	t-test.	n.s.,	not	significant.		
	 70	
2.7:	Mechanisms	of	Aurora	A	Regulation	of	YAP	Function	
2.7.1:	Inhibition	of	Aurora	A	Does	Not	Affect	Localization	of	YAP	The	 regulation	 of	 YAP	 activity	 by	 canonical	 Hippo	 pathway	 is	 through	promoting	nuclear	export	of	YAP	protein.	We	wonder	if	Aurora	A	can	regulate	YAP	activity	through	a	similar	fashion.	To	test	this,	we	treated	MDA-MB-231	cells	with	an	Aurora	A	kinase	inhibitor,	MLN8237,	and	examined	the	localization	of	YAP	protein	by	 the	 immunofluorescent	 staining.	As	 shown	 in	 the	 result,	 inhibition	of	Aurora	A	kinase	 activity	 did	 not	 affect	 the	 localization	 of	 YAP	 (Figure	 2.7.1).	 Most	 of	 YAP	proteins	can	still	stay	inside	the	nucleus	while	the	transcriptional	output	of	YAP	was	diminished.	 This	 result	 suggested	 that	 Aurora	 A	 and	 Hippo	 kinases	may	 regulate	YAP	activity	through	a	distinct	control.														
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Figure	2.7.1:	Aurora	A	Does	Not	Affect	Subcellular	Localization	of	YAP																		Confocal	microscopy	of	YAP	in	MDA-MB-231	cells	treated	with/without	MLN8237.	Scale	bar	represents	20	μm.				
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2.7.2:	 Inhibition	of	AA	Doesn’t	Affect	TEAD-YAP	 Interaction	and	 Its	Loading	on	
the	CTGF	Promoter	YAP	 protein	 has	 no	 direct	 DNA-binding	 domain	 and	 thus	 it	 relies	 on	 the	interaction	 with	 other	 DNA-binding	 transcriptional	 factors	 to	 control	 gene	expression.	TEADs	family	proteins	are	currently	considered	as	the	most	 important	partners	for	YAP’s	function,	although	many	other	factors	have	been	reported	critical	in	 a	 cell-context-dependent	 manner.	 Since	 Aurora	 A	 kinase	 can	 regulates	 TEAD-mediated	YAP	activity,	we	wondered	whether	can	Aurora	A	affect	the	interaction	of	YAP	 and	 TEAD?	 To	 test	 this	 possibility,	 MDA-MB-231	 cells	 were	 treated	 with	 an	Aurora	A	kinase	 inhibitor.	The	cell	 lysates	were	collected	 for	 immunoprecipitation	assay	to	examine	the	interaction	of	YAP	and	TEAD	protein.	As	shown	in	the	result,	YAP	strongly	 interacts	with	TEAD1	while	 inhibition	of	Aurora	A	did	not	affect	 this	interaction,	 suggesting	 Aurora	 A	 may	 not	 regulate	 YAP-TEAD	 interaction	 (Figure	2.7.2	A).			We	then	wondered	if	Aurora	A	can	affect	the	loading	of	YAP-TEAD	complex	to	the	 promoter	 region	 of	 target	 genes.	 To	 test	 this,	MDA-MB-231	 and	 BT-549-YAP-expressing	cells	were	treated	with	MLN8237	to	inhibit	Aurora	A	kinase	activity.	We	performed	 a	 chromatin-immunoprecipitation	 assay	 (ChIP)	 in	 treated	 cells	 to	monitor	the	occupancy	of	YAP	on	TEAD	site	of	the	CTGF	promoter.	As	shown	in	the	results	 (Figure	 2.7.2	 B	 and	 C),	 compared	 to	 the	 non-treated	 control	 group,	 the	occupancy	of	YAP	protein	on	CTGF	promoter	is	not	altered,	suggesting	that	Aurora	A	
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kinase	does	not	regulate	the	loading	of	YAP	complex	to	the	DNA,	at	least	not	in	the	two	cell	lines	tested.																						
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Figure	2.7.2:	Aurora	A	Does	Not	Affect	YAP-TEAD	Association	and	Its	Loading	
on	CTGF	Promoter	A									B						C						
	 75	
Figure	2.7.2:	Aurora	A	Does	Not	Affect	YAP-TEAD	Association	and	Its	Loading	
on	CTGF	Promoter		 (A) YAP	 and	 TEAD	 interaction	 was	 accessed	 by	 immunoblot.	 MDA-MB-231-FLAG-YAP	 cells	 treated	 with/without	 MLN8237	 were	 used.	 Anti-FLAG	antibody	was	used	in	pull-down,	and	the	complexes	were	eluted	with	FLAG	peptide.	(B) Chromatin	immunoprecipitation	(ChIP)	of	YAP	followed	by	qPCR	analysis	of	
CTGF	 promoter.	 MDA-MB-231	 cells	 treated	 with/without	 MLN8237	 were	used.	Error	bars	indicate	the	SD.	n.s.,	not	significant,	Student’s	t-test.	(C) Same	as	(B),	ChIP	analysis	was	performed	to	check	for	the	presence	of	YAP	on	 the	 CTGF	 promoter	 in	 BT-549-FLAG-YAP	 cells.	 Amplified	 DNA	 was	separated	in	agarose	gel	after	a	PCR.	Chromatin	immunoprecipitation	(ChIP)	of	 YAP	 followed	 by	 qPCR	 analysis	 of	 CTGF	 promoter.	 MDA-MB-231	 cells	treated	with/without	MLN8237	were	used.	Error	bars	 indicate	 the	SD.	n.s.,	not	significant,	Student’s	t-test.							
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CHAPTER	3	
DISCUSSION	AND	FUTURE	WORKS												
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3.1:	Summary	of	Current	Findings	In	 the	 current	 study,	 through	 a	 proteomic	 approach,	 we	 have	 newly	determined	that	Aurora	A	kinase	acts	as	a	positive	regulator	for	the	transcriptional	machinery	of	the	Hippo	pathway	effector,	YAP.	Specifically,	Aurora	A	interacts	with	YAP	primarily	 in	 the	nucleus.	This	 interaction	may	cause	 specific	phosphorylation	on	 the	 YAP	 protein	 and	 it	 further	 elevates	 YAP’s	 transactivation	 ability	 through	unknown	mechanisms	(Figure	3.1).	Activation	of	Aurora	A	signaling	also	promotes	the	 transforming	 ability	 of	 YAP	 in	 cell	 models.	 This	 discovery	 provides	 a	 deeper	understanding	 of	 the	 intricate	 regulatory	 network	 of	 the	 YAP	 oncoprotein.	Moreover,	 through	 analysis	 of	 YAP	mRNA	 expression	 from	 both	 patients	 and	 cell	line	 databases,	 we	 revealed	 that	 the	 expression	 of	 YAP	 well	 correlates	 with	 an	aggressive	 subtype	 of	 breast	 cancers,	 TNBC.	 Our	 results	 also	 indicate	 that	 YAP	 is	indispensable	 for	 TNBC	 cell	 growth	 in	 3D	 culture,	 suggesting	 that	 YAP	 may	exemplify	 a	 key	 node	 that	 regulates	 malignant	 development	 of	 TNBC.	 Although	further	 studies	 on	 the	biological	 role	 of	 YAP	 in	TNBC	are	necessary,	 targeting	 the	Aurora	A-YAP	axis	may	lead	to	therapeutic	benefits	in	this	disease	subset.								
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Figure	3.1:	Schematic	Model	of	Our	Findings		
				Nuclear	 Aurora	 A	 regulates	 the	 phosphorylation	 of	 YAP-S397	 and	 promotes	 the	transcriptional	activation	of	YAP.									
	 79	
3.2:	Potential	Translational	Values	from	the	Findings	Dysregulation	of	developmentally	conserved	Hippo	pathway	has	been	shown	in	multiple	 cancer	 types	 and	 overall	 it	 has	 profoundly	 contributed	 to	worsen	 the	disease	 progression.	 For	 example,	 in	 liver,	 overexpression	 of	 YAP	 or	 mutation	 of	Hippo	 cascade	 is	 sufficient	 to	 induce	 hepatocellular	 carcinoma	 (HCC).	 The	identification	 of	 Aurora	 A	 as	 a	 novel	 kinase	 that	 positively	 regulates	 YAP	 activity	may	provide	a	way	to	manage	the	malignant	phenotypes	induced	by	YAP.	There	are	several	well-defined	small	molecule	 inhibitors	 for	Aurora	A	kinase	available.	Some	of	 them	 have	 gone	 through	 clinical	 toxicity	 tests	 and	 currently	 been	 tested	 in	advanced	 clinical	 trials	 for	 cancer	 treatment.	 If	 YAP	 represents	 an	 important	downstream	effector	of	Aurora	A	kinase,	 stratifying	cancer	patients	based	on	high	YAP	expression	in	their	tumors	may	help	guide	the	treatment	of	Aurora	A	inhibitor	to	certain	population	and	increase	the	drug	response	rate.			Regarding	the	pancreatic	cancer	model,	 it	was	reported	that,	 in	experimental	mice,	expression	of	YAP	can	alleviate	the	restrain	from	Kras-dependency	(63).	And	also,	 YAP	 has	 been	 found	 at	 the	 downstream	 of	 Kras	 signaling	 and	 YAP	 is	indispensible	 for	PDAC	development	 in	one	Kras-driven	mouse	model	 (80).	Active	Kras	 mutation	 was	 found	 in	 more	 than	 85%	 of	 patients	 with	 pancreatic	adenocarcinoma	 (PDAC).	 Therefore,	 identifying	 direct	 or	 indirect	 strategies	 to	intervene	Kras	signaling	 is	of	great	 interest	 in	PDAC	treatment.	 If	Aurora	A	kinase	can	 also	 increase	 the	 activity	 of	 YAP	 in	 PDAC	 cells,	 it	 can	 be	 speculated	 that	activation	 of	 Aurora	 A	 may	 also	 help	 tumor	 cells	 escape	 from	 Kras	 inhibition.	
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Interestingly,	in	our	preliminary	result,	overexpression	of	TPX2	to	activate	Aurora	A	indeed	promotes	the	PDAC	cell	survival	when	Kras	was	shut	down	(Figure	4.2).	This	experiment	used	an	inducible	Kras-driven	mouse	cell	line,	AK196,	developed	by	Dr.	Haoqiang	 Ying	 and	 Dr.	 Ronald	 DePinho	 groups	 (63).	 Whether	 this	 TPX2-induced	phenotype	 in	 PDAC	 cells	 relies	 on	 Aurora	 A	 or	 YAP	 is	 still	 awaited	 for	 more	investigation,	 this	 result	 at	 least	 provided	 a	 potential	 clue	 to	 be	 considered	 for	future	 Kras-targeting	 therapy	 in	 PDAC.	 Intriguingly,	 TPX2	 expression	 has	 been	reported	critical	 for	maintaining	PDAC	growth	and	TPX2	protein	is	also	frequently	overexpressed	 in	 PDAC	 lines	 (139).	 The	 TPX2-Aurora	 A-YAP	 axis	 has	 a	 good	potential	waiting	for	further	examination.															
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Figure	3.2:	Activation	of	Aurora	A	Releases	Kras-Dependency	of	PDAC	Cells	
	Colony	formation	of	mouse	PDAC	cells.	This	mouse	cell	line	replies	on	Kras	to	grow.	Adding	doxycycline	 (Doxy)	 induces	 the	 expression	of	Kras.	Expression	of	YAP	has	been	 shown	 to	 let	PDAC	escape	Kras-dependency.	Here,	TPX2-expressing	PDAC	 is	tested	for	its	dependency	on	Kras.										
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3.3:	Similarity	of	Aurora	A-	and	YAP-Mediated	Cellular	Phenotypes	Identification	of	YAP	as	a	downstream	substrate	of	Aurora	A	kinase	expands	our	understanding	of	Aurora	A–mediated	malignancies.	Aurora	A	has	been	reported	to	 enhance	 not	 only	 the	 cell	 growth,	 but	 also	 cell	 migration/invasion,	 cancer	metastasis,	properties	of	cancer-initiating	cells,	and	drug	resistance	in	cancers	(119-122,	124-126).	Of	interest,	YAP	has	also	been	shown	to	be	involved	in	many	similar	functions	 (52,	 55,	 77-79),	 suggesting	 that	 the	 newly	 identified	 Aurora	 A-YAP	 axis	may	possess	a	key	role	yet	to	be	explored	in	cancer	development.		
3.4:	Enzymatic	Regulators	of	YAP	(Negative	and	Positive	Regulators)	Canonically,	YAP	activity	is	controlled	strictly	by	LATS	kinase	from	the	Hippo	pathway;	however,	there	are	several	lines	of	new	evidence	that	YAP	activity	can	also	be	 regulated	 by	 other	 kinases	 or	 protein	 methyltransferase.	 Here	 we	 review	 the	literatures	about	this	aspect	to	provide	a	better	understanding	of	post-translational	regulation	 of	 YAP	 activity.	 Each	modification	 can	 engage	 a	 distinct	 transcriptional	program	of	YAP,	depending	on	how	YAP-surrounding	complexes	are	altered.		
Negative	Regulators:	LATS	 inhibits	 YAP	 activity	 by	 direct	 phosphorylation	 on	 five	 sites	 of	 YAP.	Overall,	 it	 renders	 a	 sequestration	 of	 YAP	 in	 the	 cytoplasm	 or	 causes	 the	 protein	degradation	of	YAP	(59).			
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5'	 AMP-activated	 protein	 kinase	 (AMPK)	 has	 recently	 been	 shown	 to	 inhibit	YAP	 activity	 when	 cells	 are	 under	 energy	 stress.	 In	 one	 study,	 AMPK	 directly	phosphorylates	 on	 serine	 94	 residue	 of	 YAP	 and	 this	 abolishes	 the	 interaction	between	YAP	and	TEADs	(140).	In	another	study,	AMPK	directly	phosphorylates	S61	while	 this	 inhibits	 YAP	 activity	 by	 an	 unknown	 mechanism	 (141).	 Of	 note,	 the	second	 paper	 did	 also	 identify	 S94	 of	 YAP	 is	 an	 AMPK	 site	 but	 the	 study	 did	 not	focus	on	it.	Mutation	of	S61	to	alanine	significantly	diminishes	YAP	activity	but	it	did	affect	 neither	 the	 localization	 of	 YAP	 nor	 the	 YAP-TEAD	 interaction.	 The	 authors	suspected	that	other	unknown	dynamics	on	nuclear	YAP-complex	might	be	altered	by	AMPK.	This	mechanism	 is	 similar	 to	our	 findings	 in	 this	 thesis.	Addressing	 the	detail	 alteration	 of	 nuclear	 YAP-complex	 under	 different	 stimuli	 may	 possess	 the	key	to	understand	the	modulation	of	YAP	activity.		Protein	 methylation	 of	 YAP	 can	 also	 inhibit	 YAP	 activity.	 A	 research	 has	discovered	 that	 SET7	 methyltransferase	 can	 monomethylate	 YAP	 protein	 on	 its	lysine	494.	The	methylation	promotes	the	cytoplasmic	retention	of	YAP	protein	and	therefore	the	transcriptional	program	of	YAP	is	turned	off	(142).			
Positive	Regulators:	ABL	 tyrosine	 kinase	 was	 shown	 to	 directly	 phosphorylate	 YAP	 on	 Y357	residue.	This	phosphorylation	occurs	upon	the	DNA	damage	response.	Mechanically,	the	phosphorylation	of	YAP-Y357	promotes	the	complex	formation	of	YAP	and	p73	
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and	this	complex	later	recruits	p300	to	help	activate	apoptosis-related	genes	during	DNA	damage	(143).		YES	kinase	was	 the	 first	kinase	 found	 to	 interact	with	YAP	protein	while	 the	functional	regulation	of	YES	on	YAP	activity	was	not	 intensively	pursued	in	earlier	times.	 In	2004,	one	 study	 showed	 that	YES	kinase	 can	phosphorylate	YAP	protein	and	this	brings	the	association	of	Runx2	and	YAP.	YAP	functions	as	a	co-suppressor	of	 Runx2	 protein.	 Upon	 the	 interaction,	 YAP	 suppresses	 Runx2-mediated	 gene	transcription.	 For	 example,	 osteocalcin	 gene	 is	 a	 target.	 Inhibition	 of	 YES	 kinase	dissociates	 the	 YAP-Runx2	 complex	 and	 therefore	 those	 suppressed	 genes	 can	 be	reactivated	(144).	In	2011,	one	study	showed	that	leukemia	inhibitory	factor	(LIF)	pathway	 regulates	 YAP-TEAD2	 activity	 and	 regulates	 self-renewal	 of	 mouse	embryonic	 stem	cells	 (145).	This	 activation	 requires	YES	kinase.	 In	2012,	 another	phenomenal	 paper	 showed	 that,	 in	 colorectal	 cancer	model,	 YES	 kinase	 enhances	the	loading	of	YAP/beta-catenin	complex	to	promoters	of	BCL2L1	and	BIRC5.	In	this	study,	 TPX5	 is	 a	 critical	 transcriptional	 activator	 to	 conduct	 signal	 output	 of	YAP/beta-catenin	complex.	 Interestingly,	YES	kinase	does	not	affect	 the	binding	of	YAP	and	beta-catenin.	The	exact	mechanism	of	how	YES	kinase	regulates	the	loading	of	YAP-complex	on	target	genes	is	still	unclear	(54).		Recently,	Homeodomain-interacting	protein	kinases	(HIPKs)	have	been	shown	to	positively	regulate	YAP	activity	in	flies.	The	two	reports	all	revealed	a	critical	role	of	HIPKs	 in	 the	potentiation	of	YAP	activity	with	genetic	study.	One	study	showed	
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that	 HIPK	 can	 regulate	 the	 nuclear	 accumulation	 of	 YAP,	 while	 the	 other	 study	showed	 that	 YAP	 remains	 in	 the	 nucleus	 regardless	 of	 HIPK.	 Inhibition	 of	 HIPK	kinase	 activity	 reduces	 the	 YAP-mediated	 organ	 growth	 (146,	 147).	 Although	 the	detail	studies	in	human	cells	were	not	conducted	yet,	HIPK	may	be	also	a	promising	candidate	to	be	targeted	in	cancers.		
3.5:	Chromatin	Remodeling	Complex	and	the	Activity	of	YAP,	TAZ	Gene	 transcription	 is	 a	 complicate	 process	 that	 involves	 numerous	 protein	machineries	 to	 determine	 on	 or	 off	 of	 one	 particular	 promoter.	 Chromatin	remodeling	factors	are	essential	to	control	the	epigenetic	status	of	promoter	areas.	Human	YAP	homolog,	TAZ,	has	been	reported	to	interact	with	SWI/SNF	complex.	In	that	study,	TAZ	recruits	SWI/SNF	complex	to	promote	the	lineage	differentiation	of	breast	 epithelial	 cells	 from	 luminal	 to	 basal	 characteristics	 (148).	 YAP	 protein	 is	structurally	very	similar	to	TAZ.	It	is	possible	that	YAP	also	uses	similar	machinery	to	 control	 gene	 expression.	 Interestingly,	 from	 our	 own	 M/S	 analysis	 of	 YAP-interacting	proteins,	we	 also	observed	many	of	 SWI/SNF	members	 (Table	3.5).	 In	another	study,	drosophila	Yorkie	promotes	gene	expression	through	recruiting	the	histone	 methylation	 complex.	 YAP	 interacts	 with	 NcoA6	 to	 induce	 H3K4	methylation	on	target	genes	(149).	Preliminarily,	we	have	done	a	sucrose	gradient	separation	of	nuclear	YAP	complex	from	MDA-MB-231	cells	treated	with	an	Aurora	A	 inhibitor.	The	result	 suggested	 that	Aurora	A	may	alter	 the	size	of	nuclear	YAP-	complex	 (Figure	 3.5).	 Taken	 together,	 whether	 Aurora	 A	 may	 regulate	 the	
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transcriptional	 activity	 of	 YAP	 through	 affecting	 the	 recruitment	 of	 SWI/SNF	 or	histone-modifying	proteins	is	certainly	an	interesting	topic	for	further	study.																						
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Table	3.5:	Members	of	SWI/SNF	Complex	from	YAP-Interacting	Proteins																	This	protein	list	was	generated	from	our	M/S	analysis	of	YAP-interacting	proteins.							
SWI/SNF complex 
ARID1A 
ARID1B 
SMARCA2 
SMARCB1 
SMARCC1 
SMARCC2 
SMARCD1 
SMARCD2 
SMARCE1 
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Figure	3.5:	Aurora	A	Affects	the	Size	of	Nuclear	YAP	Protein	Complex														Immunoblot	 of	 YAP	 proteins	 in	 fractions	 collected	 from	 the	 sucrose	 gradient	separation.	Nuclear	extracts	of	MDA-MB-231	cells	 treated	with/without	MLN8237	were	used.	EZH2	is	a	nuclear	protein	and	it	servers	as	an	irrelevant	control.							
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3.6:	The	Interplay	of	Aurora	A	and	the	Upstream	Hippo	Pathway	Aurora	A	kinase,	 in	addition	 to	 interacting	with	YAP	 from	our	discovery,	has	been	 shown	 to	 interact	 with	 several	 upstream	 Hippo	 regulators.	 MST1/2	phosphorylates	 Aurora	 A	 to	 regulate	 ciliogenesis	 in	 epithelial	 cells	 (150).	 LATS2	kinase	was	 shown	 to	be	a	 substrate	of	Aurora	A,	 and	 this	 regulation	 is	 critical	 for	cytokinesis	(151,	152).	Moreover,	KIBRA,	which	associates	with	LATS	and	regulates	the	Hippo	pathway,	was	also	reported	as	a	substrate	and	regulator	of	Aurora	A	(29-32,	153).	These	lines	of	evidence	indicate	a	complex	interplay	between	Aurora	A	and	the	 Hippo	 upstream	 cascade.	 However,	 how	 Aurora	 A	 may	 directly	 or	 indirectly	affect	 the	 output	 of	 the	 Hippo	 pathway	 remains	 unanswered.	 It	 is	 plausible	 that	Aurora	A	may	also	regulate	YAP	activity	through	its	influence	on	Hippo	kinases,	and	if	 so,	 one	 would	 expect	 to	 see	 a	 change	 in	 localization	 of	 the	 YAP	 protein	 when	Aurora	 A	 activity	 is	 manipulated.	 However,	 our	 results	 showed	 that	 YAP	 protein	remains	in	the	nucleus	even	when	Aurora	A	activity	is	abrogated,	suggesting	that,	at	least	 in	our	system,	Aurora	A	could	not	significantly	 impinge	on	the	Hippo	kinases	cascade.		
3.7:	Distinct	Functions	of	Serine	397	Phosphorylation	on	the	YAP	Protein	Our	 study	 has	 determined	 that	 the	 serine	 397	 residue	 is	 a	 major	 Aurora	 A	phosphorylation	site	on	YAP.	This	phosphorylation	seems	to	elevate	YAP	activity.	Of	note,	 however,	 a	 previous	 report	 clearly	 showed	 that	 the	 same	 site	 could	 be	phosphorylated	by	LATS	kinase	and	that	 this	phosphorylation	primes	YAP	protein	for	 sequential	 phosphorylation	 by	 CK1,	 eventually	 resulting	 in	 β-TrCP–mediated	
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protein	degradation	of	YAP	 (59).	Different	 output	 from	 the	 same	phosphorylation	site	may	reflect	the	intricate	regulation	of	YAP	protein	in	a	cell	context–dependent	or	 environment	 cues–dependent	 manner.	 The	 previous	 report	 was	 conducted	 in	noncancerous	NIH-3T3	fibroblast	cells,	and	YAP	protein	stability	was	assessed	in	a	scenario	 of	 high	 cell	 density.	 In	 our	 results	 (Figure	 4.7),	when	MDA-MB-231	 cells	were	 grown	 at	 a	 high	 density,	 total	 YAP	 protein	 was	 even	 elevated	 but	 not	decreased.	However,	 in	accordance	with	 the	previous	report	 (59),	we	also	noticed	that	 high	 cell	 density	 indeed	 increased	 the	 phosphorylation	 of	 YAP-S127	 and	consequently	 reduced	 the	 expression	 of	 a	 YAP	 target	 gene,	 CTGF,	 suggesting	activation	 of	 Hippo	 kinases	 (Figure	 4.7).	 Whether	 the	 conserved	 machinery	 that	regulates	 YAP	 protein	 stability	 can	 be	 seen	 in	 both	 normal	 and	 cancerous	 cells	awaits	 further	 investigation.	 From	 another	 aspect,	 we	 observed	 that	phosphorylation	 of	 YAP	 by	 Aurora	 A	 predominantly	 occurs	 in	 the	 nuclear	compartment,	 whereas	 the	 MST/LATS	 axis	 conducts	 YAP	 phosphorylation	 in	 the	cytoplasm	 (15,	 154,	 155).	 It	 is	 possible	 that	YAP	protein,	 even	with	 the	 same	 site	phosphorylated,	may	be	differentially	regulated	in	the	nucleus	and	cytoplasm.								
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Figure	3.7:	Cell	Density	Does	Not	Decrease	YAP	Protein	Level																Immunoblot	of	YAP	and	YAP-S127p	 from	 lysates	of	MDA-MB-231	cells	cultured	at	different	densities.					
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3.8:	Roles	of	the	Nuclear	Aurora	A	kinase	In	normal	cells,	Aurora	A	expression	 is	mainly	 in	 the	cytoplasm.	However,	 in	cancerous	cells	and	a	model	system,	some	reports	have	clearly	shown	that	a	 large	portion	 of	 Aurora	 A	 protein	 localizes	 in	 the	 nucleus.	 In	 head	 and	 neck	 cancers,	nuclear	Aurora	A	was	shown	to	mediate	oncogenic	transformation	(156).	In	a	skin	tumor	 model,	 protein	 expression	 of	 Aurora	 A	 was	 shown	 in	 the	 nucleus	 (115).	Moreover,	in	Tetrahymena	model	system,	nuclear	Aurora	A	was	shown	to	regulate	the	 phosphorylation	 of	 serine	 10	 on	 histone	 H3.	 This	 histone	 phosphorylation	 is	critical	for	the	onset	of	mitosis	and	the	control	of	accurate	chromosomal	segregation	(157).	 In	 our	 results,	 we	 also	 found	 that	 Aurora	 A	 protein	 is	 almost	 exclusively	present	in	the	nucleus	of	MDA-MB-231	cells.	The	interaction	of	YAP	and	Aurora	A	is	also	 in	 the	 nucleus,	 suggesting	 a	 new	 function	 of	 nuclear	 Aurora	 A	 in	 oncogenic	progression.		
3.9:	When	Hippo	and	Aurora	A	Collide	on	YAP	Protein	In	our	study,	we	found	that	Aurora	A	kinase	regulates	YAP	only	in	the	nucleus.	However,	canonical	Hippo	pathway	was	reported	to	influence	YAP	in	the	cytoplasm.	Though	we	do	not	have	a	clear	answer	for	how	these	two	regulations	can	coordinate	with	each	other,	it	is	reasonable	to	speculate	that	Hippo	pathway	may	be	still	more	dominant	 over	 Aurora	 A-mediated	 YAP	 activity.	 The	 main	 reason	 is	 that	 Hippo	regulates	 YAP	 localization.	 Once	 YAP	 is	 trapped	 in	 the	 cytoplasm	 due	 to	 the	activation	of	Hippo,	Aurora	A	can	no	longer	enhance	YAP	activity.	Cytoplasmic	YAP	
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has	been	long	thought	non-functional;	however,	one	interesting	paper	reported	that	cytoplasmic	accumulated	YAP/TAZ	protein	can	function	as	a	scaffold	to	bridge	beta-catenin	to	the	destruction	complex	(158).	Whether	cytoplasmic	Aurora	A	may	have	any	role	to	affect	this	new	regulation	remains	to	be	determined.		
3.10:	Future	Directions	Based	on	our	current	findings,	Aurora	A	kinase	was	identified	as	a	new	kinase	that	 positively	 regulates	 YAP	 activity	 through	 a	 direct	 phosphorylation	 event.	Regarding	this	direction,	many	extended	questions	remain	to	be	tested	 for	a	more	comprehensive	understanding	of	this	new	axis.	The	potential	future	works	can	span	from	basic	researches	to	the	translational	avenue,	including	the	following:			(1) Which	subset	of	YAP-targeted	genes	is	under	the	control	of	Aurora	A	kinase?		(2) What	 are	 the	 major	 biological	 outputs,	 in	 addition	 to	 cell	 growth,	 from	Aurora	A-YAP	axis?	(3) 	There	 are	 a	 variety	 of	 transcriptional	 factors	 that	 interact	 with	 YAP.	 How	does	 Aurora	 A	 affect	 YAP	 activity	 through	 the	 interplay	 of	 different	transcriptional	factors?	At	which	scenarios,	is	Aurora	A	most	critical	for	YAP	function?		(4) What	 is	 the	 exact	 mechanism	 for	 Aurora	 A	 to	 augment	 transcriptional	activity	of	YAP?	How	is	the	dynamics	of	nuclear	YAP	complex	engaged	in	the	process?	(5) In	addition	to	TNBC,	does	this	pathway	occur	in	other	cancer	types?	
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(6) Is	 Aurora	 A	 important	 to	 regulate	 YAP-mediated	 malignancy	 in	 animal	models?	 In	 this	 case,	 does	 the	 treatment	 of	 therapeutic	 Aurora	 A	 inhibitor	improve	the	disease	control?																									
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CHAPTER	4	
MATERIALS	AND	METHODS										 			
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4.1:	Cell	Lines,	Plasmids,	and	Inhibitors	All	 cell	 lines,	 except	NIH-3T3,	were	maintained	 in	DMEM	medium	with	10%	FBS	 plus	 streptomycin	 and	 penicillin.	 NIH-3T3	 was	 purchased	 from	 ATCC	 and	maintained	in	10%	bovine	serum	in	DMEM.	Plasmids	that	express	FLAG-YAP,	FLAG-Aurora	 A,	 FLAG-TPX2,	 and	 NTAP-YAP	 were	 constructed	 on	 pCDH-CMV-MCS-EF1-Puromycin	 vector	 (#CD510B-1;	 System	 Biosciences)	 or	 pCDH-EF1-MCS-IRES-Neo	vector	 (#CD533A-2;	 System	 Biosciences)	 when	 a	 double-selection	 was	 required.	Plasmids	used	for	recombinant	protein	production	were	constructed	on	a	pET-32a	vector.	Site-directed	mutagenesis	was	induced	according	to	a	QuikChange	protocol	(Agilent	Technologies).	Primer	sequences	and	inserting	sites	are	listed	in	Table	4.1.	Other	plasmids	that	were	purchased	from	Addgene	are	listed	in	the	Plasmid	section.	For	YAP	and	Aurora	A	knockout	cells	used	in	the	experiment,	each	line	is	a	pool	of	at	least	 4	 individual	 knockout	 clones	 to	 minimize	 clonal	 variation.	 The	 knockout	efficiency	was	confirmed	by	immunoblotting.	A	CRISPR	plasmid	targeting	GFP	was	used	 as	 a	 control.	 The	 chemical	 inhibitor	 for	 Aurora	 A	 kinase,	 MLN8237,	 was	obtained	 from	 Selleck	 Chemicals.	 MLN8237	 (100nM)	 was	 used	 throughout	 the	study.							
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Table	4.1:	Primers	for	Cloning	and	Mutagenesis	
Name Purpose Site  Sequence (5’ to 3’) 
FLAG-Aurora A/F Mammalian expression Xba1 
ATA TAT TCT AGA CCA CCA TGG ACT 
ACA AGG ACG ACG ATG ACA AGA TGG 
ACC GAT CTA AAG AAA ACT GCA TTT 
CAG G 
Aurora A/R Mammalian expression BamH1 ATA TAT GGA TCC CTA AGA CTG TTT GCT AGC TGA TTC TTT GTT TTG GC 
FLAG-YAP1/F Mammalian expression EcoR1 
ATA TAT GAA TTC CCA CCA TGG ACT 
ACA AGG ACG ACG ATG ACA AGA TGG 
ATC CCG GGC AGC AGC CGC 
YAP1/R Mammalian expression Not1 
ATA TAT GCG GCC GCC TAT AAC CAT 
GTA AGA AAG CTT TCT TTA TCT AGC 
TTG G 
NTAP/F Mammalian expression Xba1 ATA TAT TCT AGA ATG GCA GGC CTT GCG CAA CAC G 
NTAP/R Mammalian expression Xba1 ATA TAT TCT AGA TCC AAC GTT AAC TGC GGT ACC TAG C 
YAP1(for NTAP)/F Mammalian expression EcoR1 
ATA TAT GAA TTC CCA CCA TGG ACT 
ACA AGG ACG ACG ATG ACA AGA TGG 
ATC CCG GGC AGC AGC CGC 
YAP(1-270)/F Bacterial expression EcoR1 ATA TAT GAA TTC ATG GAT CCC GGG CAG CAG CCG C 
YAP(1-270)/R Bacterial expression Not1 ATA TAT GCG GCC GCG TTC ATG GCA AAA CGA GGG TCA AGC 
YAP(271-504)/F Bacterial expression EcoR1 ATA TAT GAA TTC AAC CAG AGA ATC AGT CAG AGT GCT CC 
YAP(271-504)/R Bacterial expression Not1 ATA TAT GCG GCC GCT AAC CAT GTA AGA AAG CTT TCT TTA TCT AGC TTG G 
YAP(270-370)/F Bacterial expression EcoR1 ATA TAT GAA TTC AAC CAG AGA ATC AGT CAG AGT GCT CC 
YAP(270-370)/R Bacterial expression Not1 ATA TAT GCG GCC GCC ATC CCG GGA GAA GAC ACT GGA TTT TGA G 
YAP(371-504)/F Bacterial expression EcoR1 ATA TAT GAA TTC TCT CAG GAA TTG AGA ACA ATG ACG ACC 
YAP(371-504)/R Bacterial expression Not1 ATA TAT GCG GCC GCT AAC CAT GTA AGA AAG CTT TCT TTA TCT AGC TTG G 
YAP(410-504)/F Bacterial expression EcoR1 ATA TAT GAA TTC CCT CGA ACC CCA GAT GAC TTC C 
YAP(410-504)/R Bacterial expression Not1 ATA TAT GCG GCC GCT AAC CAT GTA AGA AAG CTT TCT TTA TCT AGC TTG G 
FLAG-TPX2/F Mammalian expression NheI 
ATA TAT GCT AGC CCA CCA TGG ACT 
ACA AGG ACG ACG ATG ACA AGA TGT 
CAC AAG TTA AAA GCT CTT ATT CC 
FLAG-TPX2/R Mammalian expression BamH1 ATA TAT GGA TCC TTA GCA GTG GAA TCG AGT GGA G 
YAP-397A/F Mutagenesis  
GAT GAG GCT ACA GAC AGT GGA CTA 
AGC ATG 
YAP-397A/R Mutagenesis  
GTC TGT AGC CTC ATC TCG AGA GTG 
ATA GGT G 
YAP-S127A/F Mutagenesis  GCT CAT GCC TCT CCA GCT TCT CTG C 
YAP-S127A/R Mutagenesis  
TGG AGA GGC ATG AGC TCG AAC ATG 
CTG 
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Aurora A-K162R/F Mutagenesis  
GCT CTT CGA GTG TTA TTT AAA GCT 
CAG CTG G 
Aurora A-K162R/R Mutagenesis  
TAA CAC TCG AAG AGC CAG AAT AAA 
CTT GCT TTG C 																																										
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4.2:	Transfection,	RNAi,	CRISPR,	and	Lentiviral	Infection	Plasmid	 DNA	 transfection	 was	 conducted	 with	 use	 of	 FuGENE6	 (Promega)	according	 to	 the	 manufacturer’s	 instructions.	 siRNA	 transfection	 was	 conducted	with	use	of	Amexa	Nucleofactor	II	(Lonza	Group	Ltd.,	Basel,	Switzerland)	according	to	 the	manufacturer’s	 instructions.	Lentiviral	 shRNA	 targeting	YAP	was	purchased	from	 the	 GIPZ	 lentiviral	 shRNA	 library	 (shRNA	 and	 OFRome	 Core,	 MD	 Anderson	Cancer	Center,	Houston,	TX).	The	GIPZ	lentiviral	vector	with	a	non-targeting	shRNA	was	used	as	a	scramble	control.	All	siRNAs	were	obtained	from	Sigma-Aldrich.	The	plasmid	 used	 for	 cloning	 a	 custom-designed	 CRISPR	 system	 was	 obtained	 from	Addgene	(#52961.	For	YAP	knockout	cells	(sequence:	catcagatcgtgcacgtccg)	used	in	the	 experiment,	 4	 individual	 knockout	 clones	 were	 pooled	 to	 minimize	 clonal	variation.	 The	 knockout	 efficiency	 was	 confirmed	 by	 immunoblotting.	 A	 CRISPR	plasmid	targeting	GFP	was	used	as	a	control.		Sequences	of	RNA	interference	are	listed	in	the	Table	4.2.	Lentiviral	packaging	was	 conducted	 in	 293FT	 cells	 (Thermofisher	 Scientific)	 with	 co-transfection	 of	pCMV-VSV-G	and	pCMV-dR8.2	dvpr.	 72	hours	 after	 transfection,	 and	medium	 that	contained	 viruses	 was	 used	 to	 infect	 target	 cells	 (with	 8	 µg/ml	 Polybrene)	 for	 2	days.	After	infection,	cells	were	selected	with	2	µg/ml	puromycin	or	1	mg/ml	G418	until	the	non-infected	control	cells	were	eliminated.								 	
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Table	4.2:	Information	about	qPCR,	ChIP,	RNAi,	and	CRISPR	Systems		
Name Purpose Sequences or other information 
CTGF/F qPCR CGTGTGCACCGCCAAAGATG 
CTGF/R qPCR TGCTCTGGAAGGACTCTCCG 
GAPDH/F qPCR GGT GAA GGT CGG AGT CAA CGG 
GAPDH/R qPCR ACC AGA GTT AAA AGC AGC CCT GG 
CTGF/F (for q-PCR) ChIP-qPCR TCT GTG AGC TGG AGT GTG CC 
CTGF/R (for q-PCR) ChIP-qPCR CTC GCC AAT GAG CTG AAT GG 
CTGF/F (for PCR) ChIP-PCR TCT GTG AGC TGG AGT GTG CC 
CTGF/R (for PCR) ChIP-PCR ACG CGC CGG GCT GTC G 
YAP_1 siRNA SASI_Hs01_00182403; Clone ID (From Sigma-Aldrich) 
YAP_2 siRNA SASI_Hs01_00182405; Clone ID (From Sigma-Aldrich) 
Aurora A_1 siRNA SASI_Hs01_00241477; Clone ID (From Sigma-Aldrich) 
Aurora A_2 siRNA SASI_Hs01_00241478; Clone ID (From Sigma-Aldrich) 
YAP_1 shRNA from pGIPZ library #247011 
YAP_2 shRNA from pGIPZ library #65508 
YAP1 CRISPR-sgRNA C ATC AGA TCG TGC ACG TCC G 
Aurora A CRISPR-sgRNA T GAG TCA CGA GAA CAC GTT T 
EGFP CRISPR-sgRNA GGG CGA GGA GCT GTT CAC CG 																								
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4.3:	Immunoblotting	and	Antibodies	An	 immunoblot	assay	was	 conducted	according	 to	 standard	procedures.	The	blocking	 agent	 used	 throughout	 the	 experiment	 was	 4%	 bovine	 serum	 albumin	(BSA).	Detailed	information	about	all	of	the	antibodies	used	in	the	current	study	is	listed	in	the	Table	4.3.																																				
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Table	4.3:	List	of	Antibodies	Used	in	this	Study			
Protein Company Purpose Catalog number 
YAP Cell Signaling WB, IF, IP, ChIP 14074S 
YAP Santa Cruz WB, IF Sc-271134 
YAP-S397p Cell Signaling WB, IHC 13619S 
YAP-S127p Epitomics WB 2209-1 
Actin Sigma Aldrich WB A2066 
CTGF Santa Cruz WB sc-14939 
Aurora A Cell Signaling WB, IF 4718S 
Aurora A-T288p Cell Signaling WB 3079S 
MCM5 GeneTex WB 114090 
FLAG Sigma Aldrich WB, IF, IP, ChIP F3165 
PLK1-T210p Epitomics WB 3646-1 
TPX2 Cell Signaling IHC 12245S 
Cyclin B1 Santa Cruz WB sc245 
Cyclin E Santa Cruz WB sc247 
Lamin A Santa Cruz WB sc20680 
Tubulin Sigma Aldrich WB T5168 
TEAD1 Cell Signaling WB 12292S 
EZH2 Cell Signaling WB 5246S 	 																				
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4.4:	Purification	of	Recombinant	Proteins	and	Kinase	Assay	Recombinant	 proteins	 (all	 are	 his-tagged	 proteins)	were	 produced	 in-house.	Basically,	 one	 colony	 of	 transformed	 BL21-CodonPlus	 (DE3)-RILP	 cells	 (Agilent	Technologies)	was	 inoculated	 in	 2xYT	medium	 and	 shake-incubated	 at	 30°C	 until	O.D.	 600	 reached	 0.6.	 Recombinant	 proteins	 were	 then	 purified	 according	 to	 a	QiaexpressionistTM	protocol	(Qiagen).	Eluted	proteins	were	semi-quantified	on	SDS-PAGE	 and	 compared	 with	 a	 BSA	 control.	 Enzyme	 active	 Aurora	 A	 kinase	 was	purchased	 from	 EMD	 Millipore	 (Cat.	 #14-511).	 GST-tagged	 YAP1	 protein	 was	purchased	 from	 Novus	 (Cat.	 #	 H00010413-P01).	 The	 in	 vitro	 kinase	 assay	 was	performed	at	30°C	for	20	minutes	by	mixing	25	ng	of	Aurora	A	kinase	with	750	ng	of	YAP	proteins	in	kinase	buffer	(50	mM	HEPES-7.3;	15	mM	MgCl2;	20	mM	KCl;	2	mM	EGTA;	 1	 mM	 DTT;	 100	 µM	 ATP)	 containing	 ATP	 gamma-32P.	 Reactions	 were	quenched	by	heating	at	95°C	for	5	minutes	in	the	presence	of	SDS-loading	buffer	and	then	analyzed	by	SDS-PAGE	followed	by	exposure	on	x-ray	films.		
4.5:	Tandem-Affinity	Purification	To	 purify	 YAP-binding	 proteins,	 we	 used	 the	 tandem	 affinity	 purification	(TAP)	 tag	 system,	 which	 consists	 of	 protein	 A	 and	 calmodulin-binding	 peptide	sequences	 separated	 by	 TEV	 protease	 cleavage	 site	 (159).	 	 The	 N-terminal	 TAP-tagged	YAP	or	 an	 empty	vector	was	 stably	 expressed	 in	MDA-MB-231	 cells.	Then,	the	cells	were	grown	in	50	plates	of	150	mm	culture	dishes,	and	lysed	in	TAP	lysis	buffer	 (50	 mM	 Tris-HCl	 pH8.0,	 150	 mM	 NaCl,	 1%	 Triton	 X-100,	 2	 mM	 EGTA,	
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protease	 inhibitor	 mixture,	 and	 phosphatase	 inhibitor	 mixture).	 After	 sonication	and	 centrifugation,	 the	 cleared	 cell	 lysates	 were	 subjected	 to	 purification	 as	described	 previously	 (159).	 In	 brief,	 the	 lysates	 were	 applied	 to	 the	 first	 affinity	purification	with	 rabbit	 IgG	agarose	beads.	After	 the	beads	were	washed,	 the	YAP	protein	 complex	 was	 eluted	 with	 TEV	 protease	 and	 applied	 to	 second	 affinity	purification	with	calmodulin	beads	 in	 calmodulin	binding	buffer	 (10	mM	Tris-HCl,	pH	 8.0,	 150	mM	NaCl,	 1	mM	Mg(CH3COO)2,	 2	mM	CaCl2,	 and	 0.1%	Triton	 X-100).	After	the	beads	was	washed,	the	YAP	protein	complex	was	eluted	with	EGTA	elution	buffer	 (10	mM	 β-mercaptoethanol,	 10	mM	Tris-HCl,	 pH	 8.0,	 150	mM	NaCl,	 1	mM	Mg(CH3COO)2,	 1	 mM	 imidazole,	 3	 mM	 EGTA).	 The	 eluted	 proteins	 were	 then	concentrated	with	Ultrafree®	Centifugal	Filter	(Millipore),	separated	by	SDS-PAGE,	and	stained	by	Coomassie	blue.	The	bands	were	cut	out	from	the	gel	and	subjected	to	trypsin	digestion	and	subsequent	mass	spectrometry	analysis.		
4.6:	Plasmids	The	 plasmids	 for	 the	 reporter	 assay,	 pGL2-GAL4-UAS-Luc	 (Addgene	 plasmid	#33020)(160)	 and	 pCMX-Gal4-TEAD4	 (Addgene	 plasmid	 #	 33105)	 (52),	 were	obtained	from	Addgene.	A	β-actin	promoter-driven	renilla	luciferase	construct	was	used	 as	 an	 internal	 control	 in	 the	 reporter	 assay.	 The	 plasmid	 used	 for	 cloning	 a	custom-designed	CRISPR	system	was	obtained	from	Addgene	(#52961)	(161).	The	CRISPR	targeting	sequences	of	YAP	and	Aruroa	A	were	listed	in	the	Table	4.2.			
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4.7:	Immunoprecipitation,	ChIP	assay,	and	Mass	Spectrometry	For	 immunoprecipitation,	 cell	 lysates	 were	 obtained	 with	 modified	 RIPA	buffer	(25	mM	Tris-HCl-pH	7.6,	150	mM	NaCl,	1%	NP40,	1	mM	DTT).	We	used	1	mg	of	 cell	 lysate	 in	 each	 IP	 reaction.	 Protein	 complexes	 were	 pulled	 down	 from	antibody/lysate	 (overnight	 incubation	 at	 4°C)	 by	 protein	 A/G	 beads.	 Protein	complexes	 were	 then	 washed	 3	 times	 and	 subsequently	 released	 by	 SDS-loading	buffer	or	eluted	by	FLAG	peptide	(100	µg/ml),	if	FLAG-tag	is	used.	A	ChIP	assay	was	conducted	 as	 described	 earlier	 (162).	 A	 total	 of	 2x107	 cells	 were	 used	 for	 one	reaction.	Cellular	DNA	was	sheared	 in	Bioruptor®	(Diagenode)	until	average	DNA	sizes	were	about	500	bp.	After	eluting	 the	DNA	 from	washed	beads,	 the	DNA	was	further	 purified	 by	 Qiaquick	 spin	 columns	 (Qiagen),	 and	 5%	 of	 precipitated	 DNA	was	 used	 for	 q-PCR	 analysis.	 Primers	 for	 ChIP	 are	 listed	 in	 Table	 4.2.	 Mass	spectrometric	analysis	was	performed	as	previously	described	(163).			
4.8:	RT-PCR,	q-PCR,	and	PCR	Total	cellular	RNAs	were	extracted	by	Trizol	reagent	(Thermofisher	Scientific).	We	 converted	 1	 µg	 of	 RNA	 to	 20	 µl	 cDNA	 with	 a	 SuperScript®	 VILO™	 cDNA	Synthesis	 Kit,	 according	 to	 the	 manufacturer’s	 instructions	 (Thermofisher	Scientific).	cDNA	that	has	been	converted	from	1	µg	of	RNA	can	be	used	for	a	total	of	60	 reactions	 in	 q-PCR	 analysis.	 q-PCR	 was	 conducted	 with	 iQ™	 SYBR®	 Green	Supermix	 (Bio-Rad)	 and	 analyzed	 by	 a	 CFX96	 Touch™	 Real-Time	 PCR	 Detection	System	 (Bio-Rad).	 Regular	 PCR	 amplification	 used	 Phusion®	 polymerase	 (NEB).	Primers	that	were	used	are	listed	in	Table	4.2.	
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4.9:	Reporter	Assay	The	 reporter	 assay	 was	 conducted	 as	 previously	 described(164)	 by	 co-transfection	of	plasmids	in	293FT	cells	(Thermofisher	Scientific).		
4.10:	Immunohistochemistry	IHC	staining	was	performed	by	Dr.	Weiya	Xia	as	previously	described	 (165).	Human	triple-negative	breast	cancer	tissue-microarray	slides	(n=114)	were	stained	with	antibodies	against	TPX2	and	YAP-397p	(Cell	Signaling).	The	tissue	microarrays	were	obtained	and	used	according	 to	 the	guidelines	 approved	by	 the	 Institutional	Review	 Board	 at	MD	 Anderson	 Cancer	 Center	 (IRB	 Protocol	 #	 LAB05-0127).	 The	Pearson	 Chi-Square	 test	 was	 used	 for	 statistical	 analysis	 with	 SPSS	 software.	According	 to	 histological	 scoring,	 the	 intensity	 of	 staining	 was	 ranked	 into	 four	groups:	high	(score	3),	medium	(score	2),	low	(score	1),	and	negative	(score	0).			
4.11:	Soft	Agar	Assay	Cells	 (5x103	 to	1x	104)	were	 first	mixed	with	0.3%	agar/DMEM	at	42°C	and	were	then	laid	on	top	of	0.5%	solidified	agar/DMEM	in	12-well	plates.	After	the	top	layer	solidified,	we	added	1	ml	of	fresh	medium	on	top	of	it.	Cells	were	cultured	in	the	incubator	with	continuous	changes	of	fresh	medium	every	5	days	until	the	end	point	 was	 reached.	 MTT	 (thiazolyl	 blue;	 1	 mg/ml)	 diluted	 in	 fresh	 medium	 was	added	to	stain	colonies	embedded	in	the	agar.			
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4.12:	Confocal	Microscopy	Cells	were	seeded	on	cover	slides,	treated,	and	then	fixed	in	4%	paraformaldehyde/PBS	at	room	temperature	for	12	minutes.	Fixed	cells	were	permeabilized	with	0.5%	Trion-X100/PBS	for	another	5	minutes.	Antibodies	against	proteins	of	interest	were	added	to	the	cells,	followed	by	an	overnight	incubation	at	4°C.	Secondary	antibodies	were	applied	for	1	hour	at	room	temperature.	PBS	was	used	during	the	washing	process	to	remove	traces	of	paraformaldehyde,	Triton,	or	unbound	antibodies.	Slides	were	mounted	with	mounting	solution	that	contained	DAPI.	Images	were	captured	by	a	multiphoton	confocal	laser-scanning	microscope	(Carl	Zeiss,	Thornwood,	NY,	USA).														
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